Transcription Factor Modulator

ABSTRACT

The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to A transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof; or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof.

FIELD

The present invention relates to novel agents that are useful formodulating transcription factor activity. In particular, the presentinvention relates to a transcription factor modulator that is capable ofaffecting ubiquitination, sumoylation and PIAS proteins and therebymodulation of the PIAS-regulated gene expression by STATs, p53, andother transcription factors.

BACKGROUND

Disregulation of the immune system is involved in numerous pathologies,and may be a factor that favours the establishment, maintenance orprogression of disease. Deficient immune responses or immune suppressionare known to enhance an animal's susceptibility to infection or to thedevelopment of cancer. Conversely, excessive or inappropriate immuneresponses are involved in the establishment or progression of unwantedinflammation or autoimmune conditions. It would thus be advantageous tobe able to utilize agents that modulate immune responses, and to atleast partially reverse-immune dysfunction when such dysfunction is acomponent of a given pathological condition.

The tumor suppressor protein p53 functions as a transcriptional factorthat activates genes controlling cell cycle arrest and apoptosis (see,for example, Agarwal et al., 1998, J Biol Chem, 273 (1): p 1-4; Lakin &Jackson, 1999, Oncogene, 18(53): p 7644-55; Sionov & Haupt, 1999,Oncogene, 18 (45): p 6145-6157). The activity of the p53 tumorsuppressor protein and the c-Jun proto-oncogene are regulated byposttranslational modifications, such as phosphorylation orubiquitination (Meek, 1999, Oncogene, 18(53): p 7666-75). Specifically,covalent attachment of the ubiquitin-like modifier SUMO appears tomodulate their transcriptional activity Rodriguez et al., 1999, Embo J,18(22): p 6455-61; Muller et al., 2000, J Biol Chem, 275(18): p13321-9).

Sumoylation proceeds via an enzymatic pathway that is mechanisticallyanalogous to ubiquitination, but requires a different E1-activatingenzyme and Ubc9, a SUMO-specific E2-conjugating enzyme (Lin et al.,2004, FEBS Lett, 573(1-3): p 15-8). PIAS1 act as specific E3-like ligasethat promotes sumoylation of p53 and c-Jun in vitro and in vivo. ThePIAS proteins physically interact with both p53 and c-Jun and PIAS1interacts with the tetramerization and C-terminal regulatory domains ofp53 in yeast two-hybrid analyses (Megidish et al., 2002, J Biol Chem,277(10): p 8255-9). In addition, they bind to Ubc9, suggesting that theyrecruit the E2 enzyme to their respective substrate. The SUMO ligaseactivity requires the conserved zinc-finger domain, which is distantlyrelated to the essential RING-finger motif, found in a subset ofubiquitin ligases.

PIAS proteins strongly repress the transcriptional activity of p53,suggesting that the PIAS-SUMO pathway plays a crucial role in theregulation of p53 and other transcription factors (Schmidt & Muller,2002, Proc Natl Acad Sci USA, 99 (5): p 2872-7).

The STAT-1 transcription factor has been implicated as a tumorsuppressor by virtue of its ability to inhibit cell growth and promotionof apoptosis. STAT-1 is required for optimal DNA damage-inducedapoptosis. The basal level of the p53 inhibitor Mdm2 is increased inSTAT-1(−/−) cells, suggesting that STAT-1 is a negative regulator ofMdm2 expression. STAT-1 interacts directly with p53, an association,which is enhanced following DNA damage. Therefore, in addition tonegatively regulating Mdm2, STAT-1 also acts as a co-activator for p53.Hence STAT-1 is another member of a growing family of protein partnersable to modulate the p53-activated apoptotic pathway (Townsend et al.,2004, J Biol Chem, 279(7): p 5811-20).

Signal transducer and activator of transcription 1 (STAT1) mediates geneexpression in response to cytokines and growth factors. Activation ofSTAT1 is achieved through its tyrosine phosphorylation, a process thatinvolves Jak tyrosine kinases. One of these cytokines, IFN-gamma,induces STAT1 phosphorylation and leads to expression of multiple genesand apoptosis.

Viruses can evade the host immune system by inactivating differentcomponents of the IFN-activated JAK-STAT pathway. As described earlier,members of the Paramyxovirus family of RNA viruses target STATs fordegradation. Epstein-Barr virus (EBV) inhibits the expression ofIFN-receptor through the action of the EBV immediate-early protein,BZLF1 (Morrison et al., 2001, Immunity, 15(5): p 787-99). Humancytomegalovirus inhibits IFN-induced expression of MHC class IImolecules by selectively targeting JAK1 for degradation (Miller et al.,1998, J Exp Med, 187(5): p 675-83). By contrast, infection withvaricella-zoster virus inhibits the expression of STAT1 and JAK2, butnot JAK1 (Abendroth et al., 2000, J Virol, 74(4): p 1900-7). Individualswith defects in the IFN-JAK-STAT pathway show increased susceptibilityto viruses and intracellular bacteria. Patients with mutations in theIFN-receptor chains are susceptible to infection with mycobacteria(Dupuis et al., 2000, Immunol Rev, 178: p 129-37). Recently, patientswith STAT1 deficiency have been reported (Dupuis et al., 2003, NatGenet, 33(3): p 388-91). These individuals suffered from mycobacterialinfection and died of lethal viral disease.

The aetiopathology of Crohn's disease—a chronic inflammatory boweldisease—is poorly understood. Mice with tissue-specific disruption ofStat3 during haematopoiesis show Crohn's disease-like pathogenesis(Welte et al., 2003, Proc Natl Acad Sci USA, 100(4): p 1879-84). Inaddition, constitutively tyrosine phosphorylated STAT3 is found inintestinal T cells from patients with Crohn's disease (Lovato et al.,2003, J Biol Chem, 278(19): p 16777-81). These results indicate that thedysregulation of STAT3 signaling might be involved in the pathogenesisof Crohn's disease. However, the exact role of STAT3 in the pathogenesisof Crohn's disease is not understood.

Apart from its affect on the JAK/STAT pathway, PIAS1 has been shown tobe a negative regulator of the NF-KB signaling (Liu et al., 2005, MolCell Biol, 25(3): p 1113-23). The NF-KB family of transcription factorsis activated by a wide variety of signals to regulate a spectrum ofcellular processes. The proper regulation of NF-KB activity is critical,since abnormal NF-KB signaling is associated with a number of humanillnesses, such as chronic inflammatory diseases and cancer. Uponcytokine stimulation, the p65 subunit of NF-KB translocates into thenucleus, where it interacts with PIAS1. The binding of PIAS1 to p65inhibits cytokine-induced NF-KB-dependent gene activation. PIAS1 blocksthe DNA binding activity of p65 both in vitro and in vivo.

The ubiquitin-proteolysis system, which was discovered a little over 20years ago by Hershko and Ciechanover, was originally thought toeliminate “old”, damaged, misfolded or misassembled proteins (Hershko &Ciechanover, 1998, Annu Rev Biochem, 67: p 425-79; Hershko et al., 2000,Nat Med, 6(10): p 1073-81). The system acquired its name from a 76-aminoacid (aa) ubiquitously expressed protein, which is highly conserved inall eukaryotes. The ubiquitin pathway consists of several componentsthat act sequentially in a hierarchical mode: a concerted two-stepreaction that results in a high-energy thioester linkage betweenubiquitin and a single conserved ubiquitin-activating enzyme (E1) andubiquitin transfer through trans-acylation to one of severalubiquitin-conjugating enzymes (Ubcs or E2s). The latter collaborate witha large series of E3s (protein-ubiquitin ligases) in attaching ubiquitinmolecules to the ε-amino group of the substrate's lysine residues, thuscreating a reversible isopeptide bond. Pathways critical to cancer andimmune regulation are regulated at several steps by polyubiquitination(Hershko & Ciechanover, 1998, supra; Ciechanover et al., 2000, J CellBiochem Suppl, 34: p 40-51; Schwartz & Hochstrasser, 2003, TrendsBiochem Sci, 28(6): p 321-8; Ben-Neriah, 2002, Nat Immunol, 3(1): p20-6).

Recent focus on the system has emphasized its role in controllingcellular processes via two modes of action. These areproteolysis-associated polyubiquitination for controlling the abundanceof regulatory proteins and proteolysis-independent ubiquitination:mono-, multi- or polyubiquitination of regulatory proteins (Ciechanoveret al., 2000, Bioessays, 22(5): p 442-51). When the ubiquitins arelinked to each other through the lysine amino acid found at position 48of each ubiquitin, the target protein is directed to the cellularwaste-disposal unit, the proteasome (Amit & Ben-Neriah, 2003, SeminCancer Biol, 13(1): p 15-28). If lysine 63 is used instead, it can serveas a signal for the target to assemble with other proteins (Wang et al.,2001, Nature, 412(6844): p 346-51; Deng et al., 2000, Cell, 103(2): p351-61).

For proteolysis-associated ubiquitination, a further, poorlycharacterized, catalytic step is required: polymerization of a ubiquitinchain, which is facilitated by the same E2-E3 pair that attached thefirst ubiquitin molecule to the substrate or by additional enzymaticcomponents. The polyubiquitin chain then serves as a recognition markerfor the substrate-degrading 26S protein complex, the proteasome.

Parallel to the “classical” ubiquitination systems, there are otherrelated enzymatic pathways that covalently attach ubiquitin-likemolecules (Ubls) to target proteins for diverse purposes (Hochstrasser,2000, Nat Cell Biol, 2(8): pE153-7; Jentsch & Pyrowolakis, 2000, TrendsCell Biol, 10(8): p 335-42). Ubls are not only structurally related toubiquitin, but conjugate to their protein targets through aubiquitination-like enzymatic process, that is, formation of anisopeptide bond between the Ubl COOH-terminal glycine and an amino groupof a target protein lysine. In addition, Ubl conjugation is done byenzymes that are related to ubiquitin pathway E1 and E2s (Hochstrasser,2000, supra; Jentsch & Pyrowolakis, 2000, supra). Certain Ublmodifications may support protein ubiquitination: an example is theattachment of the Nedd8 Ubl to a subunit of the IB E3 protein thatresults in enhanced IB ubiquitination (Read et al., 2000, Mol Cell Biol,20(7): p 2326-33; Kawakami et al., 2001, Embo J, 20(15): p 4003-12).Other Ubl modifications may interfere with protein ubiquitination, forexample, the attachment of SUMO (small ubiquitin modifier) Ubl to IB,which suppresses its ubiquitination (Hay, 2001, Trends Biochem Sci,26(5): p. 332-3), or have ubiquitination-unrelated functions, such asregulating nuclear protein export (Mahajan et al., 1997, Cell, 88(1): p97-107).

Whereas a single E1 activates ubiquitin, many (at least 25 in mammals)E2 species have been characterized in every eukaryotic organism. Themultitude of E2 enzymes indicates that they specialize in distinctubiquitination processes; however, the biochemical basis for thisputative specialization is mostly unknown. Whereas E2 proteins areidentified by their homology, the E3s constitute a highly heterogeneousclass of proteins, which nevertheless can be classified into threegroups: HECT (homologous to E6-AP COOH-terminus), RING and Ufd2-related(U-box) E3s (Weissman, 2001, Nat Rev Mol Cell Biol, 2(3): p 169-78;Jackson et al., 2000, Trends Cell Biol, 10(10): p 429-39). The HECT E3sare related to E6-associated protein (E6-AP)—the E3 that targets p53 incomplex with papillomavirus E6 protein—and share a 350-aa HECT domain.HECT E3s have a unique mode of action: they catalyze ubiquitin transferto the substrate through an intermediate thiol-ester between ubiquitinand a conserved cysteine in the HECT domain. In contrast, it appearsthat the RING E3s do not directly participate in the chemical transferof ubiquitin to the substrate, but merely coordinate the activity oftheir associated E2s (Meroni & Diez-Roux, 2005, Bioessays, 27(11): p1147-57).

RING E3s are distinguished by the metal-coordinated RING-finger motif.The RING E3s are either single proteins with a substrate-targetingmotif, such as an SH2 domain, or multi-subunit protein complexes inwhich substrate-targeting and the RING function are carried out bydifferent proteins. Some of the most remarkable recent advances in theubiquitin field have been made in characterizing the composition,partial structure and mode of substrate-recognition of three largemultisubunit RING E3s: APC/C (anaphase-promoting complex-cyclosome), SCF(Skp1-cullin-1-F-box protein) and VCB (VHL-elongin C-elongin B complex)(Jackson et al., 2000, Trends Cell Biol, 10(10): p 429-39; Deshaies etal., 1999, Annu Rev Cell Dev Biol, 15: p 435-67; Zachariae & Nasmyth,1999, Genes Dev, 13(16): p 2039-58; Kondo & Kaelin, 2001, Exp Cell Res,264(1): p 117-25). U-box E3s constitute a newly identified class, someof which may mediate the assembly of polyubiquitin chains on proteinsubiquitinated by other E3s (Hatakeyama et al., 2001, J Biol Chem,276(35): p 33111-20).

Having a fundamental regulatory role in every eukaryotic organism, it isnot surprising that proteolysis-associated ubiquitination also fulfillsan important role in the immune system. Proteolysis-associatedubiquitination drives a variety of immunity-related regulatory events,from transcriptional activation to apoptosis (Shmueli & Oren, 2005,Cell, 121(7): p 963-5). Parallel to well establishedproteolysis-associated ubiquitination, there are importantproteosome-mediated degradation events in which the precise role ofubiquitination is still unclear; among the latter, antigen-processing isa prominent example (Kloetzel, 2001, Nat Rev Mol Cell Biol, 2(3): p179-87; Yewdell, 2001, Trends Cell Biol, 11(7): p 294-7).

Ubiquitination of transcription factors can control their activityindependently of proteosomal degradation. For example, Met4, a bZIPfactor that regulates a large number of genes predominantly involved inmethionine biosynthesis, is ubiquitinated but not degraded in thepresence of high intracellular levels of S-adenosylmethionine (Kaiser etal., 2000, Cell, 102(3): p 303-14). Ubiquitination inactivates Met4 atleast in part because it precludes recruitment of the coactivator, Cbf1(Kaiser et al., 2000, supra); in addition, binding of Met4 to a subclassof its target promoters is compromised by ubiquitination (Kuras et al.,2002, Mol Cell, 10(1): p 69-80). Ubiquitination does not necessarilyinhibit transcription factors since ubiquitination of the HIVTat proteinby Mdm2 augments its ability to activate transcription (Bres et al.,2003, Nat Cell Biol, 5(8): p 754-61). Similarly, ubiquitination of Mycby Skp2 contributes to transcriptional activation, potentially byallowing Myc to recruit proteasomal subunits that have aproteolysis-independent role in transcriptional activation (Ferdous etal., 2001, Mol Cell, 7(5): p 981-91). Two signals are known to determinewhether ubiquitination leads to degradation. Proteolytic substrates aremodified by polyubiquitin chains, and a minimum chain length of aboutfour ubiquitin residues appears to be required to target the attachedprotein to the proteasome (Flick et al., 2004, Nat Cell Biol, 6(7): p634-41). The lysine residue of ubiquitin, used for polyubiquitin chainformation, specifies the second signal. Whereas chains linked throughlysine 48 usually lead to proteasomal degradation, those linked throughlysine-63 of ubiquitin do not target proteins to the proteasome (Bres etal., 2003, supra).

The TRIM/RBCC proteins are defined by the presence of the tripartitemotif composed of a RING domain, one or two B-box motifs and acoiled-coil region (Reymond et al., 2001, Embo J, 20(9): p 2140-51).These proteins are involved in a plethora of cellular processes such asapoptosis, cell cycle regulation and viral response. Consistently, theiralteration results in many diverse pathological conditions. The highlyconserved structure of these proteins suggests that a common biochemicalfunction may underlie their assorted cellular roles. Some TRIM/RBCCproteins are implicated in ubiquitination and propose that this largeprotein family represents a novel class of ‘single protein RING finger’ubiquitin E3 ligases (Meroni & Diez-Roux, 2005, supra).

Ubiquitin ligases play a key role in protein localization,transcriptional modulation and protein turnover within the cell.Modulation of these targets presents a novel approach to treatingdiseases where the normal cell processes are out of balance, such as incancer where the cell cycling is abnormal. Ubiquitin ligase cancertargets play a role in the regulation of stability, localization, andactivity of key proteins such as oncoproteins and tumour suppressorgenes. Ubiquitin ligase targets are numerous and modular. This providesthe potential for intervening in a highly specific fashion in a disease,potentially improving efficacy and minimizing side-effects.

It can be seen that transcription factors play a major role inhomeostasis, especially with respect to the immune system. Accordingly,if modulators or regulators of transcription factors like thosediscussed above can be identified it might be possible to regulate cellproliferation, migration, and/or differentiation.

SUMMARY

Inventors have shown that HLS5 is a potent activator on the IFN-gammaactivation site (GAS)-like elements located upstream of a luciferasereporter. Also HLS5 can be co-immunoprecipitated with PIAS and caninduce its degradation. These results demonstrate that by regulatingPIAS and ubiquitination, HLS5 modulates gene expression by transcriptionfactors such as STATs.

Accordingly, in a first aspect the present invention provides atranscription factor modulator comprising:

(i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoformthereof, functional fragment thereof or pharmaceutical compositionthereof; or

(ii) a compound or composition capable of regulating the endogenouslevels of HLS-5 or its activity; or

(iii) combinations thereof.

In a second aspect the present invention provides a ubiquitin ligasecomprising:

(i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoformthereof, functional fragment thereof or pharmaceutical compositionthereof; or

(ii) a compound or composition capable of regulating the endogenouslevels of HLS-5 or its activity; or

(iii) combinations thereof.

In some embodiments, the HLS-5 polypeptide will comprise the sequenceset out in SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 or a polypeptidesubstantially homologous thereto, or a functional fragment thereof.

It is to be clearly understood that the HLS-5 polypeptide of the presentinvention also includes polypeptide analogues, including but not limitedto the following:

1. HLS-5 polypeptide in which one or more amino acids is replaced by itscorresponding D-amino acid. The skilled person will be aware thatretro-inverso amino acid sequences can be synthesised by standardmethods. See for example Chorev and Goodman, 1993, Acc Chem Res, 26:266-273;2. Peptidomimetic compounds of HLS-5, in which the peptide bond isreplaced by a structure more resistant to metabolic degradation. See,for example, Olson et al, 1993, J. Med. Chem., 36, p 3039-3049.3. HLS-5 polypeptide in which individual amino acids are replaced byanalogous structures, for example gem-diaminoalkyl groups oralkylmalonyl groups, with or without modified termini or alkyl, acyl oramine substitutions to modify their charge.

The use of such alternative structures can provide significantly longerhalf-life in the body, since they are more resistant to breakdown underphysiological conditions.

Methods for combinatorial synthesis of polypeptide analogues and forscreening of polypeptides and polypeptide analogues are well known inthe art (see, for example, Gallop et al., 1994, J. Med. Chem., 37, p1233-1251). It is particularly contemplated that the HLS-5 polypeptidesof the invention are useful as templates for design and synthesis ofcompounds of improved activity, stability and bioavailability.

Preferably where amino acid substitution is used, the substitution isconservative, i.e., an amino acid is replaced by one of similar size andwith similar charge properties.

In some embodiments, the HLS-5 polypeptide will be expressed in vivofrom a vector comprising a polynucleotide encoding HLS-5. In someembodiments, the HLS-5 polynucleotide will be selected from the groupconsisting of:

(a) polynucleotides comprising the nucleotide sequence set out in SEQ IDNO:1, SEQ ID NO:3 or SEQ ID NO:5, or a functional fragment thereof;

(b) polynucleotides comprising a nucleotide sequence capable ofhybridizing selectively to the nucleotide sequence set out in SEQ IDNO:1, SEQ ID NO:3 or SEQ ID NO:5, or a functional fragment thereof;

(c) polynucleotides comprising a polynucleotide sequence which isdegenerate as a result of the genetic code to the polynucleotidesdefined in (a) or (b);

(d) polynucleotides complementary to the polynucleotides of (a) or (b).

The present invention also provides a vector comprising a HLS-5polynucleotide of the invention, for example an expression vectorcomprising a HLS-5 polynucleotide of the invention, operably linked toregulatory sequences capable of directing expression of saidpolynucleotide in a host cell.

Accordingly, in a third aspect, the present invention provides atranscription factor modulator comprising a vector comprising a HLS-5polynucleotide of the invention, operably linked to regulatory sequencescapable of directing expression of said polynucleotide in a host cell.

In some embodiments, the transcription factor modulator acts as aubiquitin ligase.

In a fourth aspect the present invention provides a method of modulatingtranscription factor activity in vivo comprising the step ofadministering to a subject in need thereof:

(i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoformthereof, functional fragment thereof or pharmaceutical compositionthereof; or

(ii) a compound or composition capable of regulating the endogenouslevels of HLS-5 or its activity; or

(iii) combinations thereof.

In some embodiments, the transcription factor modulator will negativelycontrol transcription factor activity i.e. directly or indirectlyprevent transcription factor function and/or reverse transcriptionfactor activity. In yet other embodiments, the transcription factormodulator will positively control transcription factor activity i.e.directly or indirectly bring about or enhance transcription factoractivity.

In a fifth aspect the present invention provides a method of modulatingtranscription factor activity in vitro comprising the step ofadministering to cells:

(i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoformthereof, functional fragment thereof or pharmaceutical compositionthereof; or

(ii) a compound or composition capable of regulating the endogenouslevels of HLS-5 or its activity; or

(iii) combinations thereof.

In a sixth aspect the present invention provides a method for treatingor preventing a condition associated with transcription factordisregulation comprising the step of administering to a subject in needthereof:

(i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoformthereof, functional fragment thereof or pharmaceutical compositionthereof; or

(ii) a compound or composition capable of regulating the endogenouslevels of HLS-5 or its activity; or

(iii) combinations thereof.

In some embodiments the condition will be directly affected by, orcontrolled by, transcription factors. In other embodiments, thecondition will not be directly affected by or controlled bytranscription factors; however, the administration of the transcriptionfactor modulator improves, alleviates or treats the condition bycontrolling the transcription factors associated with or affected by thecondition.

The transcription factor modulator of the invention may be administeredby any suitable route, and the person skilled in the art will readily beable to determine the most suitable route and dose for the condition tobe treated. Dosage will be at the discretion of the attendant physicianor veterinarian, and will depend on the nature and state of thecondition to be treated, the age and general state of health of thesubject to be treated, the route of administration, and any previoustreatment which may have been administered.

The transcription factor modulator may be administered in the form of acomposition further comprising a pharmaceutically acceptable carrier.This will usually comprise at least one excipient, for example selectedfrom the group consisting of sterile water, sodium phosphate, mannitol,sorbitol, sodium chloride, and any combination thereof.

Methods and pharmaceutical carriers for preparation of pharmaceuticalcompositions are well known in the art, as set out in textbooks such asRemington's Pharmaceutical Sciences, 20th Edition, Williams & Wilkins,Pennsylvania, USA.

The carrier or diluent, and other excipients, will depend on the routeof administration, and again the person skilled in the art will readilybe able to determine the most suitable formulation for each particularcase.

The subject may be a human, or may be a domestic, companion or zooanimal. While it is particularly contemplated that the transcriptionfactor modulator of the invention is suitable for use in medicaltreatment of humans, it is also applicable to veterinary treatment,including treatment of companion animals such as dogs and cats, anddomestic animals such as horses, cattle and sheep, or zoo animals suchas non-human primates, felids, canids, bovids, and ungulates.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the domain structure of HLS5, and the yeast two-hybridinteraction with PIAS1.

FIG. 2 represents a Western blot that shows the in vivo association ofPIAS1 with HLS-5 by co-immunoprecipitation.

FIG. 3 represents fluorescence microscopy images that demonstrateextensive FLAG-PIAS1 colocalisation with HLS-5 at nuclear foci whenproteosomal degradation is inhibited.

FIG. 4 represents a Western blot that indicates a reduction of PIAS1expression occurs when PIAS1 and HLS5 are co-transfected into COS cells.

FIG. 5 presents luciferase promoter reporter activity indicating thatintroduction of exogenous HLS-5 into Hela cells strongly activates thetranscriptional response to interferon ligands from the GAS promoter,but not the ISRE promoter.

FIG. 6 represents Western blots that indicate that IL-6 in M1 myeloidcells, and PMA in HL-60 cells, strongly increase HLS-5 proteinexpression.

FIG. 7 a shows the structural domains of HLS5, while FIG. 7 b describeshuman TRIM/RBCC proteins with E3 activity in vitro or in vivo. FIG. 7 cshows multiple overlapping clones from a single gene, encoding a proteinalternatively named UBC9, Cezanne, UBA52.

FIG. 8 represents Western blots of cell lysates (bottom panel) and HLS5immunoprecipitates from HA-Ubiquitin expressing cells (top panel).Changes in the high-molecular-weight anti-HA-signal in the top panelhighlight the role of the RING-finger motif in auto-ubiquitination.

FIG. 9 represents Western blots of FLAG-PIAS immunoprecipitated fromHA-Ubiquitin expressing cells, and shows that in the presence ofexogenous HLS-5, the transfected PIAS1 becomes poly-ubiquitinated.

FIG. 10 represents Western blots indicating that oligo 06 reducesGFP-HLS5 levels, relative to β-actin

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Before describing the present invention in detail, it is to beunderstood that this invention is not limited to particularlyexemplified HLS-5 sequences, expression techniques or methods and may,of course, vary. It is also to be understood that the terminology usedherein is for the purpose of describing particular embodiments of theinvention only, and is not intended to be limiting which will be limitedonly by the appended claims.

All publications, patents and patent applications cited herein, whethersupra or infra, are hereby incorporated by reference in their entirety.However, publications mentioned herein are cited for the purpose ofdescribing and disclosing the protocols and reagents which are reportedin the publications and which might be used in connection with theinvention. Nothing herein is to be construed as an admission that theinvention is not entitled to antedate such disclosure by virtue of priorinvention.

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, recombinant DNA, pharmacology and immunology, whichare within the skill of the art. Such techniques are described in theliterature. See, for example, Bailey & Ollis, 1986, “BiochemicalEngineering Fundamentals”, 2nd Ed., McGraw-Hill, Toronto; Coligan etal., 1999, “Current protocols in Protein Science” Volume I and II (JohnWiley & Sons Inc.); “DNA Cloning: A Practical Approach”, Volumes I andII (Glover ed., 1985); Handbook of Experimental Immunology, Volumes I-IV(Weir & Blackwell, eds., 1986); Immunochemical Methods in Cell andMolecular Biology (Mayer and Walker, eds., Academic Press, London,1987), Methods in Enzymology, Vols. 154 and 155 (Wu et al. eds. 1987);“Molecular Cloning: A Laboratory Manual”, 2^(nd) Ed., (ed. by Sambrook,Fritsch and Maniatis) (Cold Spring Harbor Laboratory Press: 1989);“Nucleic Acid Hybridization”, (Hames & Higgins eds. 1984);“Oligonucleotide Synthesis” (Gait ed., 1984); Remington's PharmaceuticalSciences, 17^(th) Edition, Mack Publishing Company, Easton, Pa., USA.;“The Merck Index”, 12^(th) Edition (1996), Therapeutic Category andBiological Activity Index; and “Transcription & Translation”, (Hames &Higgins eds. 1984).

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural reference unless thecontext clearly dictates otherwise. Thus, for example, a reference to “anucleic acid molecule” includes a plurality of such molecules, and areference to “an agent” is a reference to one or more agents, and soforth. Unless defined otherwise, all technical and scientific terms usedherein have the same meanings as commonly understood by one of ordinaryskill in the art to which this invention belongs. Although any materialsand methods similar or equivalent to those described herein can be usedto practice or test the present invention, the preferred materials andmethods are now described.

The present invention encompasses the following aspects: preparation ofa transcription factor modulator of the present invention; preparationof the polynucleotide encoding said HLS-5 polypeptide or a recombinantvector carrying and expressing said polynucleotide; transformantscarrying said vector; methods of producing said transformants; methodsof detecting the HLS-5 polypeptide; methods of detecting the mRNA orpolynucleotide encoding said HLS-5 polypeptide; and methods of treatingconditions caused by or exacerbated by unregulated transcription factoractivity are explained below.

In the description that follows, if there is no instruction, it will beappreciated that techniques such as gene recombinant techniques,production of recombinant polypeptides in animal cells, insect cells,yeast and Escherichia coli, molecular-biological methods, methods ofseparation and purification of expressed HLS-5 polypeptides, assays andimmunological methods, are well-known in this field and any suchtechnique may be adopted.

In its broadest aspect the present invention provides a transcriptionfactor modulator comprising a pharmaceutically-effective amount of aHLS-5, isoform thereof or functional fragment thereof.

The term “transcription factor modulator” as used herein refers to acompound or composition of matter that is capable of affecting directlyor indirectly the activity of a transcription factor. As describedsupra, transcription factors are able to bind to specific sets of shortconserved sequences contained in each promoter. Some of these elementsand factors are common, and are found in a variety of promoters and usedconstitutively; others are specific and their use is regulated. In someembodiments, the transcription factors of the present invention arethose associated with PIAS1 and in particular, the p53 pathway.Non-limiting examples of possible transcription factors include PIAS1,c-jun, p53, STAT and NF-KB

In some embodiments, the transcription factor modulator activity is as aubiquitin ligase. The term “ubiquitin ligase” as used herein refers to acompound or composition of matter that is capable of affecting directlyor indirectly the ubiquitination of proteins. Therefore, as describedsupra, polypeptides referred to herein as possessing the activity of“ubiquitination”, e.g., such as with regard to the activity of a“ubiquitin ligase”, are understood to be capable of forming a thiolester adduct with the C-terminal carboxyl group of ubiquitin andtransferring the ubiquitin to an s-amino group in an acceptor protein byformation of an isopeptide bond.

In some embodiments of the present invention the “transcription factormodulator” is HLS-5. HLS-5 is a member of the RING finger B-boxCoiled-coil (RBCC) protein family (Lalonde et al., 2004, J Biol Chem,279, 8181-8189). This group of molecules is also referred to as thetripartite motif family (TRIM) of proteins, because of thecharacteristic domain architecture that is conserved amongst highereukaryotes (Reymond et al., 2001, Embo J, 20, 2140-2151). Sequenceanalysis of the mouse and human genomes has identified a diverse arrayof RBCC proteins, many with unknown functions (Reymond et al., 2001,supra). Several RBCC family members, including PML, TIF1α and Rfp, aremutated in human cancer, implicating RBCC proteins as crucial regulatorsof cell growth and differentiation (de The et al 1991, Cell,66:675-684). HLS-5 maps to chromosome 8p21, a region frequently deletedin a variety of tumours, and enforced expression of the gene in HeLacells reduced cell growth, clonogenicity and tumorigenicity (Lalonde etal., 2004, supra). Recent studies have demonstrated that some RBCCmembers regulate the activity, or steady-state levels, of partnerproteins by influencing subcellular localization or post-translationalmodifications (Diamonti et al., 2002, Proc Natl Acad Sci USA, 99,2866-2871; Pearson et al., 2000, Nature, 406, 207-210; Urano et al.,2002, Nature, 417, 871-875).

HLS-5 was originally identified as a gene markedly up-regulated duringan erythroid to myeloid lineage switch of the J2E erythroid cell line(Klinken et al., 1988, Proc. Natl. Acad. Sci., USA, 85, 8506-8510;Lalonde et al., 2004, supra). The myeloid variants displayed amonoblastoid morphology, did not respond to erythropoietin (EPO) and hadreduced expression of erythroid-specific transcription factors,including GATA-1 and EKLF (Keil et al., 1995, Cell Growth Differ., 6,439-448; Williams et al., 1999, Embo J., 18, 5559-5566). Significantly,HLS-5 was isolated independently as a gene induced during macrophagecolony stimulating factor—initiated maturation of myeloid cells (Kimuraet al., 2003, J. Biol. Chem., 278, 25046-25054).

Therefore, in some embodiments of the present invention the“transcription factor modulator” comprises an isolated full-length HLS-5polypeptide. The term “polypeptide” refers to a polymer of amino acidsand its equivalent and does not refer to a specific length of theproduct; thus, peptides, oligopeptides and proteins are included withinthe definition of a polypeptide. This term also does not refer to, orexclude modifications of the polypeptide, for example, glycosylations,acetylations, phosphorylations, and the like. Included within thedefinition are, for example, polypeptides containing one or more analogsof an amino acid (including, for example, natural amino acids, etc.),polypeptides with substituted linkages as well as other modificationsknown in the art, both naturally and non-naturally occurring.

Full length HLS-5 polypeptides of the present invention have about 500amino acids, encode a tumour suppressor factor in an animal,particularly a mammal, and include allelic variants or homologues. Fulllength HLS-5 polypeptides also typically comprise a Ring finger motif, aB box, a coiled-coil motif and an SPRY motif. HLS-5 polypeptides of theinvention also include fragments and derivatives of full length HLS-5polypeptides, particularly fragments or derivatives having substantiallythe same biological activity. The polypeptides can be prepared byrecombinant or chemical synthetic methods. In some embodiments, theHLS-5 polypeptides include those comprising the amino acid sequence ofSEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or allelic variants orhomologues, including fragments, thereof. In further embodiments, theHLS-5 polypeptides consist essentially of amino acids 12 to 504 of theamino acid sequence shown as SEQ ID NO:4 or allelic variants, homologuesor fragments, thereof.

In the context of the present invention, a homologous sequence is takento include an amino acid sequence which is at least 60, 70, 80 or 90%identical, preferably at least 95 or 98% identical at the amino acidlevel over at least 20, 50, 100, 200, 300 or 400 amino acids with theamino acid sequences set out in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 orSEQ ID NO:8. In particular, homology should typically be considered withrespect to those regions of the sequence known to be essential for thefunction of the protein rather than non-essential neighbouringsequences. Thus, for example, homology comparisons are preferably madeover regions corresponding to the Ring finger, B box, coiled coil and/orSPRY domains of the HLS-5 amino acid sequence set out in SEQ ID NO:2,SEQ ID NO:4 or SEQ ID NO:8. The ring finger corresponds to approximatelyamino acids 36 to 75 of SEQ ID NO:2. The B box corresponds toapproximately amino acids 111 to 152 of SEQ ID NO:2. The coiled coilcorresponds to approximately amino acids 219 to 266 of SEQ ID NO:2.

The SPRY domain corresponds to approximately amino acids 368 to 507 ofSEQ ID NO:2. In some embodiments, polypeptides of the invention comprisea contiguous sequence having greater than 50, 60 or 70% homology, morepreferably greater than 80 or 900 homology, to one or more of aminoacids 111 to 152, 219 to 266 or 368 to 507 of SEQ ID NO:2 or thecorresponding regions of SEQ ID NO:4 or SEQ ID NO:6.

In some embodiments, polypeptides may alternatively or in additioncomprise a contiguous sequence having greater than 80 or 90% homology,to amino acids 36 to 75 of SEQ ID NO:2 or the corresponding region ofSEQ ID NO:4 or SEQ ID NO:6. Other polypeptides comprise a contiguoussequence having greater than 40, 50, 60, or 706 homology, morepreferably greater than 80 or 90% homology to amino acids 1 to 35, 76 to110, 153 to 218 and/or 267 to 367 of SEQ ID NO:2 or the correspondingregions of SEQ ID NO:4 or SEQ ID NO:6. Although homology can also beconsidered in terms of similarity (i.e. amino acid residues havingsimilar chemical properties/functions), in the context of the presentinvention it is preferred to express homology in terms of sequenceidentity. The terms “substantial homology” or “substantial identity”,when referring to polypeptides, indicate that the polypeptide or proteinin question exhibits at least about 70% identity with an entirenaturally-occurring protein or a portion thereof, usually at least about80% identity, and preferably at least about 90 or 95% identity.

Homology comparisons can be conducted by eye, or more usually, with theaid of readily available sequence comparison programs. Thesecommercially available computer programs can calculate percentagehomology between two or more sequences.

Percent (%) homology may be calculated over contiguous sequences, i.e.one sequence is aligned with the other sequence and each amino acid inone sequence directly compared with the corresponding amino acid in theother sequence, one residue at a time. This is called an “ungapped”alignment. Typically, such ungapped alignments are performed only over arelative short number of residues (for example less than 50 contiguousamino acids).

Although this is a very simple and consistent method, it fails to takeinto consideration that, for example, in an otherwise identical pair ofsequences, one insertion or deletion will cause the following amino acidresidues to be put out of alignment, thus potentially resulting in alarge reduction in % homology when a global alignment is performed.Consequently, most sequence comparison methods are designed to produceoptimal alignments that take into consideration possible insertions anddeletions without penalising unduly the overall homology score. This isachieved by inserting “gaps” in the sequence alignment to try tomaximise local homology.

However, these more complex methods assign “gap penalties” to each gapthat occurs in the alignment so that, for the same number of identicalamino acids, a sequence alignment with as few gaps aspossible—reflecting higher relatedness between the two comparedsequences—will achieve a higher score than one with many gaps. “Affinegap costs” are typically used that charge a relative high cost for theexistence of a gap and a smaller penalty for each subsequent residue inthe gap. This is the most commonly used gap scoring system. High gappenalties will of course produce optimised alignments with fewer gaps.Most alignment programs allow the gap penalties to be modified. However,it is preferred to use the default values when using such software forsequence comparisons. For example, when using the GCG Wisconsin Bestfitpackage the default gap penalty for amino acid sequences is −12 for agap and −4 for each extension.

Calculation of maximum % homology therefore firstly requires theproduction of an optimal alignment, taking into consideration gappenalties. A suitable computer program for carrying out such analignment is the GCG Wisconsin Bestfit package (University of Wisconsin,USA; Devereux et al., 1984, Nucleic Acids Research, 12: 387). Examplesof other software than can perform sequence comparisons include, but arenot limited to, the BLAST package (see, Ausubel et al., supra), FASTA(Altschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWORKS suiteof comparison tools. Both BLAST and FASTA are available for offline andonline searching (see Ausubel et al., supra, pages 7-58 to 760). Howeverit is preferred to use the GCG Bestfit program.

Although the final % homology can be measured in terms of identity, thealignment process itself is typically not based on an all-or-nothingpair comparison. Instead, a scaled similarity score matrix is generallyused that assigns scores to each pairwise comparison based on chemicalsimilarity or evolutionary distance. An example of such a matrixcommonly used is the BLOSUM62 matrix—the default matrix for the BLASTsuite of programs. GCG Wisconsin programs generally use either thepublic default values or a custom symbol comparison table if supplied(see user manual for further details). It is preferred to use the publicdefault values for the GCG package, or in the case of other software,the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible tocalculate % homology, preferably % sequence identity. The softwaretypically does this as part of the sequence comparison and generates anumerical result.

HLS-5 polypeptide homologues include those having the amino acidsequences, wherein one or more of the amino acids are substituted withanother amino acid which substitutions do not substantially alter thebiological activity of the molecule.

An HLS-5 polypeptide homologue according to the invention preferably has80% or greater amino acid sequence identity to the human HLS-5polypeptide amino acid sequence set out in SEQ ID NO:4 or SEQ ID NO:6.Examples of HLS-5 polypeptide homologues within the scope of theinvention include the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6wherein: (a) one or more aspartic acid residues is substituted withglutamic acid; (b) one or more isoleucine residues is substituted withleucine; (c) one or more glycine or valine residues is substituted withalanine; (d) one or more arginine residues is substituted withhistidine; or (e) one or more tyrosine or phenylalanine residues issubstituted with tryptophan.

“Protein modifications or functional fragments” are also encompassed bythe term “transcription factor modulator” when it refers to HLS-5polypeptides. HLS-5 polypeptides or fragments thereof which aresubstantially homologous to primary structural sequence but whichinclude, e.g., in vivo or in vitro chemical and biochemicalmodifications or which incorporate unusual amino acids. Suchmodifications include, for example, acetylation, carboxylation,phosphorylation, glycosylation, ubiquitination, labelling, e.g., withradionucleotides, and various enzymatic modifications, as will bereadily appreciated by those well skilled in the art.

A HLS-5 polypeptide “fragment,” “portion” or “segment” is a stretch ofamino acid residues of at least about five to seven contiguous aminoacids, often at least about seven to nine contiguous amino acids,typically at least about nine to 13 contiguous amino acids and, mostpreferably, at least about 20 to 30 or more contiguous amino acids,wherein said “fragment,” “portion” or “segment” has substantiallysimilar function to wild type full length HLS-5 polypeptide.

“Substantially similar function” refers to the function of thepolypeptide homologue, variant, derivative or fragment of HLS-5 withreference to the wild-type HLS-5 polypeptide. The “fragment,” “portion”or “segment” of HLS-5 should retain is ability to control thesumoylation proteins as shown by (Boggio et al., 2004, Mol Cell, 16,549-561). In some embodiments, the “fragment,” “portion” or “segment”,will comprise one or more domains that have been identified in otherproteins as being important with respect to function. For example, theB30.2/SPRY domain and an additional domain in huTRIM5alpha, comprisingthe amino-terminal RING and B-box components of the TRIM motif, havebeen shown to be required for N-MLV restriction activity, while theintervening coiled-coil domain is necessary and sufficient forhuTRIM5alpha multimerization. Truncated huTRIM5alpha proteins that lackeither or both the N-terminal RING/B-Box or the C-terminal B30.2/SPRYdomain form heteromultimers with full-length huTRIM5alpha and aredominant inhibitors of its N-MLV restricting activity, suggesting thathomomultimerization of intact huTRIMsalpha monomers is necessary forN-MLV restriction. However, localization in large cytoplasmic bodies isnot required for inhibition of N-MLV by huTRIM5alpha or for inhibitionof HIV-1 by chimeric or rhTRIM5alpha (Yap et al., 2005, Curr Biol, 15,73-78). Geminin is a cellular protein that associates with Cdtl andinhibits Mcm2-7 loading during S phase. It prevents multiple cycles ofreplication per cell cycle and prevents episome replication. Gemininforms a parallel coiled-coil homodimer with atypical residues in thedimer interface. Point mutations that disrupt the dimerization abolishinteraction with Cdtl and inhibition of replication. This interaction isessential for replication inhibition (Saxena et al., 2004, Mol Cell, 15,245-258). Therefore, it is highly likely that functional fragments,portions or segments of HLS-5 will have one or more of the regionsidentified above. Moreover, techniques well known in the art foridentifying or testing the activity of these regions can be used to testor identify if the HLS-5 fragment, portion or segment of the presentinvention is functional.

In addition to the similarity of function, the modified polypeptide mayhave other useful properties, such as a longer half-life.

In some embodiments, the HLS-5 fragment is an isoform of HLS-5. HLS-5,like other TRIM proteins, are defined by a cluster of three differentRBCC or TRIM protein motifs: a RING motif, which is cysteine-rich andbinds zinc; one or two so-called B boxes, which also bind zinc; and acoiled-coil domain that is probably involved in the formation of proteincomplexes. All individual TRIM proteins homo-oligomerization and somemight also form alliances with other TRIM proteins(hetero-oligomerization). There are at least 37 TRIM family members inhumans (Reymond et al., 2001, Embo J, 20, 2140-2151). Many TRIM familymembers have alternative splicing, with the best characterised membersbeing TRIM39 (PML) (Duprez et al., 1999, J Cell Sci, 112, 381-393),TRIM18 (MID1) (Berti et al., 2004, BMC Cell Biol, 5, 9), TRIM32(LGMD-2H) (Schoser et al., 2005, Ann Neurol, 57, 591-595) and TRIM5 (Xuet al., 2003, Exp Cell Res, 288, 84-93). Each of the various TRIMproteins seems to localize to particular compartments within cells,forming discrete structures to which they entice other proteins, withdifferent isoforms potentially attracting different subsets of proteinsand with alternate functions (Reymond et al., 2001, supra). Based uponthe foregoing, HLS-5 has at least one isoform.

The HLS-5 isoform shown in SEQ ID NO:6 includes an alternate exon in thecoding region which results in a frame shift and an early stop codon,compared to HLS-5 shown in SEQ ID NO:4. SEQ ID NO:6 isoform is shorterand has a distinct C-terminus compared to HLS-5 in SEQ ID NO:4.

In certain embodiments, the HLS-5 transcription factor modulators arepeptidyl compounds (including peptidomimetics) of HLS-5 which have beenmodified such that they resist or are more resistant to proteolyticdegradation and the like. These peptidyl compounds might includefunctional groups, such as in place of the scissile peptide bond, whichfacilitates inhibition of a serine-, cysteine- or aspartate-typeprotease, as appropriate. For example, the HLS-5 peptidyl compound canbe a peptidyl diketone or a peptidyl keto ester, a peptidehaloalkylketone, a peptide sulfonyl fluoride, a peptidyl boronate, apeptide epoxide, a peptidyl diazomethanes, a peptidyl phosphonate,isocoumarins, benzoxazin-4-ones, carbamates, isocyantes, isatoicanhydrides or the like. Such functional groups have been provided inother peptide molecules, and general routes for their synthesis areknown. See, for example, Angelastro et al., 1990, J. Med. Chem.33:11-13; Bey et al., EPO 363,284; Bey et al., EPO 364,344; Grubb etal., WO 88/10266; Higuchi et al., EPO 393,457; Ewoldt et al., 1992,Molecular Immunology, 29(6):713-721; Hernandez et al., 1992, Journal ofMedicinal Chemistry, 35(6): 1121-1129; Vlasak et al., 1989, J. Virology63(5):2056-2062; Hudig et al., 1991, J. Immunol., 147(4):1360-1368;Odakc et al., 1991, Biochemistry, 30(8):2217-2227; Vijayalakshmi et al.,1991, Biochemistry, 30(8):2175-2183; Kam et al., 1990, Thrombosis &Haemostasis, 64(1):133-137; Powers et al., 1989, J. Cell Biochem.,39(1):33-46; Powers et al., Proteinase Inhibitors, Barrett et al., Eds.,Elsevier, pp. 55-152 (1986); Powers et al., 1990, Biochemistry,29(12):3108-3118; Oweida et al., 1990, Thrombosis Research,58(2):391-397; Hudig et al., 1989, Molecular Immunology, 26(8):793-798;Orlowski et al., 1989, Archives of Biochemistry & Biophysics,269(1):125-136; Zunino et al., 1988, Biochimica et Biophysica Acta.,967(3):331-340; Kam et al., 1988, Biochemistry, 27(7):2547-2557; Parkeset al., 1985, Biochem J., 230:509-516; Green et al., 1981, J. Biol.Chem., 256:1923-1928; Angliker et al., 1987, Biochem. J., 241:871-875;Puri et al., 1989, Arch. Biochem. Biophys. 27:346-358; Hanada et al.,Proteinase Inhibitors: Medical and Biological Aspects, Katunuma et al.,Eds., Springer-Verlag pp. 25-36 (1983); Kajiwara et al., 1987, Biochem.Int., 15:935-944; Rao et al., 1987, Thromb. Res., 47:635-637; Tsujinakaet al., 1988, Biochem. Biophys. Res. Commun. 153:1201-1208). See alsoU.S. Pat. No. 4,935,493; U.S. Pat. No. 5,462,928; U.S. Pat. No.5,543,396; U.S. Pat. No. 5,296,604; and U.S. Pat. No. 6,201,132.

In other embodiments, the HLS-5 polypeptide is a non-peptidyl compound,e.g., which can be identified by such drug screening assays as describedherein. These non-peptidyl compounds can be, merely to illustrate,synthetic organics, natural products, nucleic acids or carbohydrates.

Also included are such peptidomimetics as olefins, phosphonates,aza-amino acid analogs and the like.

Also deemed as equivalents are any HLS-5-based compounds which can behydrolytically converted into any of the aforementioned HLS-5 compoundsincluding boronic acid esters and halides, and carbonyl equivalentsincluding acetals, hemiacetals, ketals, and hemiketals, and cyclicdipeptide analogs.

The present invention also encompasses pharmaceutically acceptable saltsof the HLS-5 compounds include the conventional non-toxic salts orquaternary ammonium salts of the compounds, e.g., from non-toxic organicor inorganic acids. For example, such conventional non-toxic saltsinclude those derived from inorganic acids such as hydrochloride,hydrobromic, sulphuric, sulfonic, phosphoric, nitric, and the like; andthe salts prepared from organic acids such as acetic, propionic,succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic,palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic,salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.

The pharmaceutically acceptable salts of the present invention can besynthesized from the HLS-5 compounds which contain a basic or acidmoiety by conventional chemical methods. Generally, the salts areprepared by reacting the free base or acid with stoichiometric amountsor with an excess of the desired salt-forming inorganic or organic acidor base in a suitable solvent.

Contemplated equivalents of the HLS-5 compounds described above includecompounds which otherwise correspond thereto, and which have the samegeneral properties thereof (e.g. the ability to control sumoylation),wherein one or more simple variations of substituents are made which donot adversely affect the efficacy of the HLS-5 molecule in use in thecontemplated methods. In general, the HLS-5 polypeptides of the presentinvention may be prepared by the methods described below, or bymodifications thereof, using readily available starting materials,reagents and conventional synthesis procedures. In these reactions, itis also possible to make use of variants which are in themselves known,but are not mentioned here.

By the terms “amino acid residue” and “peptide residue” is meant anamino acid or peptide molecule without the —OH of its carboxyl group. Ingeneral the abbreviations used herein for designating the amino acidsand the protective groups are based on recommendations of the IUPAC-IUBCommission on Biochemical Nomenclature (see Biochemistry (1972)11:1726-1732). For instance Met, Ile, Leu, Ala and Gly represent“residues” of methionine, isoleucine, leucine, alanine and glycine,respectively. By the residue is meant a radical derived from thecorresponding α-amino acid by eliminating the OH portion of the carboxylgroup and the H portion of the α-amino group. The term “amino acid sidechain” is that part of an amino acid exclusive of the —CH(NH₂)COOHportion, as defined by Kopple, 1966, “Peptides and Amino Acids”, W ABenjamin Inc., New York & Amsterdam, pp 2 and 33; examples of such sidechains of the common amino acids are —CH₂CH₂SCH₃ (the side chain ofmethionine), —CH₂(CH₃)—CH₂CH₃ (the side chain of isoleucine),—CH₂CH(CH₃)₂ (the side chain of leucine) or H— (the side chain ofglycine).

For the most part, the amino acids used in the application of thisinvention are those naturally occurring amino acids found in proteins,or the naturally occurring anabolic or catabolic products of such aminoacids which contain amino and carboxyl groups.

The term “amino acid residue” further includes analogs, derivatives andcongeners of any specific amino acid referred to herein, as well asC-terminal or N-terminal protected amino acid derivatives (eg. modifiedwith an N-terminal or C-terminal protecting group). For example, thepresent invention contemplates the use of amino acid analogs wherein aside chain is lengthened or shortened while still providing a carboxyl,amino or other reactive precursor functional group for cyclization, aswell as amino acid analogs having variant side chains with appropriate,functional groups). For instance, the HLS-5 polypeptide can include anamino acid analog such as, for example, cyanoalanine, canavanine,djenkolic acid, norleucine, 3-phosphoserine, homoserine,dihydroxy-phenylalanine, 5-hydroxytryptophan, 1-methylhistidine,3-methylhistidine, diaminiopimelic acid, ornithine, or diaminobutyricacid. Other naturally occurring amino acid metabolites or precursorshaving side chains which are suitable herein will be recognized by thoseskilled in the art and are included in the scope of the presentinvention.

Also included are the (D) and (L) stereoisomers of such amino acids whenthe structure of the amino acid admits of stereoisomeric forms. Theconfiguration of the amino acids and amino acid residues herein aredesignated by the appropriate symbols (D), (L) or (DL), furthermore whenthe configuration is not designated the amino acid or residue can havethe configuration (D), (L) or (DL). It will be noted that the structureof some of the compounds of this invention includes asymmetric carbonatoms. It is to be understood accordingly that the isomers arising fromsuch asymmetry are included within the scope of this invention. Suchisomers can be obtained in substantially pure form by classicalseparation techniques and by sterically controlled synthesis. For thepurposes of this application, unless expressly noted to the contrary, anamed amino acid shall be construed to include both the (D) or (L)stereoisomers.

The phrase “protecting group” as used herein means substituents whichprotect the reactive functional group from undesirable chemicalreactions. Examples of such protecting groups include esters ofcarboxylic acids and boronic acids, ethers of alcohols and acetals andketals of aldehydes and ketones. For instance, the phrase “N-terminalprotecting group” or “amino-protecting group” as used herein refers tovarious amino-protecting groups which can be employed to protect theN-terminus of an amino acid or peptide against undesirable reactionsduring synthetic procedures. Examples of suitable groups include acylprotecting groups such as, to illustrate, formyl, dansyl, acetyl,benzoyl, trifluoroacetyl, succinyl and methoxysuccinyl; aromaticurethane protecting groups as, for example, benzyloxycarbonyl (Cbz); andaliphatic urethane protecting groups such as t-butoxycarbonyl (Boc) or9-Fluorenylmethoxycarbonyl (FMOC).

Certain polypeptides of the present invention may exist in particulargeometric or stereoisomeric forms. The present invention contemplatesall such forms, including cis- and trans-isomers, R- and S-enantiomers,diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof,and other mixtures thereof, as, falling within the scope of theinvention. Additional asymmetric carbon atoms may be present in asubstituent such as an alkyl group. All such isomers, as well asmixtures thereof, are intended to be included in this invention.

The similarity of function (activity) of the modified HLS-5 polypeptidemay be substantially the same as the activity of the wild type HLS-5polypeptide. Alternatively, the similarity of function (activity) of themodified polypeptide may be higher than the activity of the wild-typeHLS-5 polypeptide. The function/biological activity of homologues,variant, derivatives or fragments relative to wild type may bedetermined, for example, by means of biological assays. For example,when administered to HeLa or COS cells, HLS-5 reduces levels of PIAS1,UBC9 and SUMO-1, which results in a reduction of the overall SUMOylationof some protein products and the induction of others. Thus, one in vivoassay involves the testing for HLS-5 modulation of protein SUMOylationby the administration a variant of HeLa or COS cell, i.e. tissue, etc.and determination of whether cells have altered levels of SUMOylation ofindividual protein products by western analysis. Preferred homologues,variants and fragments are capable of inhibiting SUMOylation by a factorof at least 0.5 relative to full length HLS-5, preferably by a factor ofat least 0.9. Another test, based on the interaction of HLS-5 withelements of the SUMOylation machinery is to do in vitro SUMO-1modification assay. Basically, a reaction mixture of 20 μl containing 1μg of tagged protein of interest as the substrate as well as 1 μg of E1(GST-Uba2, His6-Aos1), 2 μg of E2 (Ubc9), and 1 μg of SUMO-1 in asolution comprising 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 10 mM ATP, 2 mMMgCl₂, and 0.1 mM dithiothreitol is incubated for 2 h at 30° C. (see,for example, Hatakeyama et al., 2001, J Biol Chem, 276, 33111-33120).This assay can be done in the presence or absence of HLS-5. The reactionis terminated by the addition of SDS sample buffer containing 50%β-mercaptoethanol and heating at 88° C. for 5 min. Samples can then befractionated by SDS-PAGE on a 12% gel and subjected to immunoblotanalysis with mouse monoclonal antibodies to SUMO-1 (2 μg/ml,anti-GMP-1), Myc (1 μg/ml, 9E10), or GST (1 μg/ml), according to the tagused. Immune complexes can be detected with horseradishperoxidase-conjugated rabbit polyclonal antibodies to mouseimmunoglobulin. To determine the extent of inhibition of proteinsubstrate, variant or fragment to HLS-5 in an in vitro SUMOylationassay. Preferred homologues, variants and fragments are capable ofbinding to HLS5 by a factor of at least 0.5 relative to full lengthHLS-5, preferably by a factor of at least 0.9. Suitable in vitroSUMOylation assays are well known to skilled persons, such as‘SUMOylation’ assays where one substrate is added to the components ofthe SUMOylation machinery and the modified or “SUMOylation” products arequantified or observed.

As described supra, in some embodiments, the transcription factormodulator activity is as a ubiquitin ligase. Accordingly; in someembodiments, the variant or modified ubiquitin ligase can be testedusing an in vitro ubiquitination assay. Briefly, logarithmically growingHeLa cells can be collected at a density of 6×10⁵ cells/ml. Cells arearrested in G1 by 48-hour treatment with 70 μM lovastatin as described(O'Connor &. Jackman, 1995, in Cell Cycle-Materials and Methods, M.Pagano, ed., Springer, N.Y., Chap. 6). 1 μl of in vitro translated[³⁵S]p27 is incubated at 30° C. for different times (0-75 minutes) in 10μl of ubiquitination mix containing: 40 mM Tris pH7.6, 5 mM MgCl₂, 1 mMDTT, 10% glycerol, 1 μM ubiquitin aldehyde, 1 mg/ml methyl ubiquitin, 10mM creatine phosphate, 0.1 mg/ml creatine phosphokinase, 0.5 mM ATP, 1Mokadaic acid, 20-30 μg HeLa cell extract. Ubiquitin aldehyde can beadded to the ubiquitination reaction to inhibit the isopeptidases thatwould remove the chains of ubiquitin from p27. Addition of methylubiquitin competes with the ubiquitin present in the cellular extractsand terminates p27 ubiquitin chains. Such chains appear as discretebands instead of a high molecular smear. These shorter polyubiquitinchains have lower affinity for the proteasome and therefore are morestable. Reactions are terminated with Laemmli sample buffer containing.beta.-mercaptoethanol and the products can be analyzed on protein gelsunder denaturing conditions.

Polyubiquitinated p27 forms are identified by autoradiography. p27degradation assay is performed in a similar manner, except that (i)Methylated ubiquitin and ubiquitin aldehyde are omitted; (ii) Theconcentration of HeLa extract is approximately 7 μg/μl; (iii) Extractsare prepared by hypotonic lysis (Pagano et al., 1995, Science 269:682),which preserves proteasome activity better than the nitrogen bombdisruption procedure. In the absence of methyl ubiquitin, p27degradation activity, instead of p27 ubiquitination activity, can bemeasured.

The samples are immunoprecipitated with an antibody to p27 followed by asubsequent immunoprecipitation with an anti-ubiquitin antibody and runon an 8% SDS gel. The high molecular species as determined by this assayare ubiquitinated. As a control, a p27 mutant lacking all 13 lysines canbe used.

Other methods of testing ubiquitination are described in the examplesinfra.

The modified polypeptide may be synthesised using conventionaltechniques, or is encoded by a modified nucleic acid and produced usingconventional techniques. The modified nucleic acid is prepared byconventional techniques. A nucleic acid with a function substantiallysimilar to the wild-type HLS-5 gene function produces the modifiedprotein described above.

Besides substantially full-length polypeptides, the present inventionprovides for biologically active fragments of the polypeptides.Biologically active fragments are those polypeptide fragments retainingtranscription modulating activity.

The present invention also provides for fusion polypeptides, comprisingHLS-5 polypeptides and fragments. Homologous polypeptides may be fusionsbetween two or more HLS-5 polypeptide sequences or between the sequencesof HLS-5 and a related protein. Likewise, heterologous fusions may beconstructed which would exhibit a combination of properties oractivities of the derivative proteins.

For example, ligand-binding or other domains may be “swapped” betweendifferent new fusion polypeptides or fragments. Such homologous orheterologous fusion polypeptides may display, for example, alteredstrength or specificity of binding. Fusion partners includeimmunoglobulins, bacterial β galactosidase, trpE, protein A,β-lactamase, alpha amylase, alcohol dehydrogenase and yeast alpha matingfactor.

Fusion proteins will typically be made by either recombinant nucleicacid methods, as described below, or may be chemically synthesized.

“Protein purification” refers to various methods for the isolation ofthe HLS-5 polypeptides from other biological material, such as fromcells transformed with recombinant nucleic acids encoding HLS-5, and arewell known in the art. For example, such polypeptides may be purified byimmuno-affinity chromatography employing, eg., the antibodies providedby the present invention. Various methods of protein purification arewell known in the art.

The terms “isolated”, “substantially pure”, and “substantiallyhomogeneous” are used interchangeably to describe a HLS-5 polypeptidethat has been separated from components that accompany it in its naturalstate. A monomeric protein is substantially purified when at least about60 to 75% of a sample exhibits a single polypeptide sequence. Asubstantially purified protein will typically comprise about 60 to 90%W/W of a protein sample, more usually about 95%, and preferably will beover about 99% pure. Protein purity or homogeneity may be indicated by anumber of means well known in the art, such as polyacrylamide gelelectrophoresis of a protein sample, followed by visualizing a singlepolypeptide band upon staining the gel. For certain purposes, higherresolution may be provided by using HPLC or other means well known inthe art which are utilized for application.

A HLS-5 polypeptide is substantially free of naturally associatedcomponents when it is separated from the native contaminants thataccompany it in its natural state.

Thus, a HLS-5 polypeptide that is chemically synthesised or synthesisedin a cellular system different from the cell from which it naturallyoriginates will be substantially free from its naturally associatedcomponents. A protein may also be rendered substantially free ofnaturally associated components by isolation, using protein purificationtechniques well known in the art.

A HLS-5 polypeptide produced as an expression product of an isolated andmanipulated genetic sequence is an “isolated polypeptide,” as usedherein, even if expressed in a homologous cell type. Synthetically madeforms or molecules expressed by heterologous cells are inherentlyisolated molecules.

In some embodiments of the present invention the terms “HLS-5 protein”or “HLS-5 polypeptide” refers to a protein or polypeptide encoded by aHLS-5 polynucleotide sequence, variants or functional fragments thereof.Also included are HLS-5 polypeptide encoded by DNA that hybridize underhigh stringency conditions, to HLS-5 encoding polynucleotides andclosely related polypeptides retrieved by antisera to the HLS-5protein(s). Accordingly, in some embodiments, the term “transcriptionfactor modulator” comprises an HLS-5 polynucleotide molecule thatencodes an HLS-5 polypeptide, allelic variant, or analog, includingfunctional fragments, thereof.

Preferred polynucleotide molecules according to the invention includethe polynucleotide sequences set out in SEQ ID NO:1 and SEQ ID NO:3 orfunctional fragments thereof.

A polynucleotide is said to “encode” a polypeptide if, in its nativestate or when manipulated by methods well known to those skilled in theart, it can be transcribed and/or translated to produce the RNA forand/or the polypeptide or a fragment thereof. The anti-sense strand isthe complement of such a nucleic acid, and the encoding sequence can bededuced therefrom.

An “isolated” or “substantially pure” nucleic acid (e.g., RNA, DNA or amixed polymer) is one which is substantially separated from othercellular components which naturally accompany a native human sequence orprotein, e.g., ribosomes, polymerases, many other human genome sequencesand proteins. The term embraces a nucleic acid sequence or protein thathas been removed from its naturally occurring environment, and includesrecombinant or cloned DNA isolates and chemically synthesized analogs oranalogs biologically synthesized by heterologous systems.

“HLS-5 gene sequence,” “HLS-5 gene,” “HLS-5 nucleic acids” or “HLS-5polynucleotide” include coding sequences, intervening sequences andregulatory elements controlling transcription and/or translation. Theterm “HLS-5 gene sequence” is intended to include all allelic variationsof the DNA sequence.

These terms, when applied to a nucleic acid, refer to a nucleic acidthat encodes a HLS-5 polypeptide, fragment, homologue or variant,including, e.g., protein fusions or deletions. The nucleic acids of thepresent invention will possess a sequence that is either derived from,or substantially similar to a natural HLS-5 encoding gene or one havingsubstantial homology with a natural HLS-5 encoding gene or a portionthereof. The coding sequence for murine HLS-5 polypeptide is shown inSEQ ID NO:1, with the amino acid sequence shown in SEQ ID NO:2. Thecoding sequence for human HLS-5 polypeptide is shown in SEQ ID NO:3 andSEQ ID NO:7, with the amino acid sequence shown in SEQ ID NO:4 and SEQID NO:8.

A nucleic acid or fragment thereof is “substantially homologous” (“orsubstantially similar”) to another if, when optimally aligned (withappropriate nucleotide insertions or deletions) with the other nucleicacid (or its complementary strand), there is nucleotide sequenceidentity in at least about 60% of the nucleotide bases, usually at leastabout 70%, more usually at least about 80%, preferably at least about90%, and more preferably at least about 95-98% of the nucleotide bases.

Alternatively, substantial homology or (identity) exists when a nucleicacid or fragment thereof will hybridise to another nucleic acid (or acomplementary strand thereof) under selective hybridisation conditions,to a strand, or to its complement. Selectivity of hybridisation existswhen hybridisation that is substantially more selective than total lackof specificity occurs. Typically, selective hybridisation will occurwhen there is at least about 55% identity over a stretch of at leastabout 14 nucleotides, preferably at least about 65%, more preferably atleast about 75%, and most preferably at least about 90%. The length ofhomology comparison, as described, may be over longer stretches, and incertain embodiments will often be over a stretch of at least about ninenucleotides, usually at least about 20 nucleotides, more usually atleast about 24 nucleotides, typically at least about 28 nucleotides,more typically at least about 32 nucleotides, and preferably at leastabout 36 or more nucleotides.

Thus, polynucleotides of the invention preferably have at least 75%,more preferably at least 85%, more preferably at least 90% homology tothe sequences shown in the sequence listings herein. More preferablythere is at least 95%, more preferably at least 98%, homology.Nucleotide homology comparisons may be conducted as described below forpolypeptides. A preferred sequence comparison program is the GCGWisconsin Best fit program described below. The default scoring matrixhas a match value of 10 for each identical nucleotide and −9 for eachmismatch. The default gap creation penalty is −50 and the default gapextension penalty is −3 for each nucleotide.

In the context of the present invention, a homologous sequence is takento include a nucleotide sequence which is at least 60, 70, 80 or 90%identical, preferably at least 95 or 98% identical at the amino acidlevel over at least 20, 50, 100, 200, 300, 500 or 1000 nucleotides withthe nucleotides sequences set out in SEQ ID NO:1 or SEQ ID NO:3. Inparticular, homology should typically be considered with respect tothose regions of the sequence that encode contiguous amino acidsequences known to be essential for the function of the protein ratherthan non-essential neighbouring sequences. Thus, for example, homologycomparisons are preferably made over regions corresponding to the Ringfinger, B box, coiled coil and/or SPRY domains of the HLS-5 amino acidsequence set out in SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:8.

Preferred polypeptides of the invention comprise a contiguous sequencehaving greater than 50, 60 or 70% homology, more preferably greater than80, 90, 95 or 976 homology, to one or more of the nucleotides sequencesof SEQ ID NO:1 which encode amino acids 111 to 152, 219 to 266 or 368 to507 of SEQ ID NO:2 or the equivalent nucleotide sequences in SEQ IDNO:3.

Preferred polynucleotides may alternatively or in addition comprise acontiguous sequence having greater than 80, 90, 95 or 97% homology tothe sequence of SEQ ID NO: 1 that encodes amino acids 36 to 75 of SEQ IDNO:2 or the corresponding nucleotide sequences of SEQ ID NO:3. Otherpreferred polynucleotides comprise a contiguous sequence having greaterthan 40, 50, 60, or 70% homology, more preferably greater than 80, 90,95 or 97% homology to the sequence of SEQ ID NO:1 that encodes aminoacids 1 to 35, 76 to 110, 153 to 218 and/or 267 to 367 of SEQ ID NO:2 orthe corresponding nucleotide sequences of SEQ ID NO:3.

Nucleotide sequences are preferably at least 15 nucleotides in length,more preferably at least 20, 30, 40, 50, 100 or 200 nucleotides inlength.

Generally, the shorter the length of the polynucleotide, the greater thehomology required to obtain selective hybridization. Consequently, wherea polynucleotide of the invention consists of less than about 30nucleotides, it is preferred that the % identity is greater than 75%,preferably greater than 90% or 95% compared with the HLS-5 nucleotidesequences set out in the sequence listings herein.

Conversely, where a polynucleotide of the invention consists of, forexample, greater than 50 or 100 nucleotides, the % identity comparedwith the HLS-5 nucleotide sequences set out in the sequence listingsherein may be lower, for example greater than 50%, preferably greaterthan 60 or 75%.

Nucleic acid hybridisation will be affected by such conditions as saltconcentration, temperature, or organic solvents, in addition to the basecomposition, length of the complementary strands, and the number ofnucleotide base mismatches between the hybridizing nucleic acids, aswill be readily appreciated by those skilled in the art. Stringenttemperature conditions will generally include temperatures in excess of30° C., typically in excess of 37° C., and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1000 mM,typically less than 500 mM, and preferably less than 200 mM. However,the combination of parameters is much more important than the measure ofany single parameter. An example of stringent hybridization conditionsis 65° C. and 0.1×SSC (1×SSC=0.15M NaCl, 0.015M sodium citrate pH 7.0).

The “polynucleotide” compositions of this invention include RNA, cDNA,genomic DNA, synthetic forms, and mixed polymers, both sense andantisense strands, and may be chemically or biochemically modified ormay contain non-natural or derivatized nucleotide bases, as will bereadily appreciated by those skilled in the art. Such modificationsinclude, for example, labels, methylation, substitution of one or moreof the naturally occurring nucleotides with an analog, internucleotidemodifications such as uncharged linkages (e.g., methyl phosphonates,phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages(e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties(e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.),chelators, alkylators, and modified linkages (e.g., alpha anomericnucleic acids, etc.). Also included are synthetic molecules that mimicpolynucleotides in their ability to bind to a designated sequence viahydrogen bonding and other chemical interactions.

Such molecules are known in the art and include, for example, those inwhich peptide linkages substitute for phosphate linkages in the backboneof the molecule. The present invention provides recombinant nucleicacids comprising all or part of the HLS-5 region. The recombinantconstruct may be capable of replicating autonomously in a host cell.Alternatively, the recombinant construct may become integrated into thechromosomal DNA of the host cell. Such a recombinant polynucleotidecomprises a polynucleotide of genomic, cDNA, semi-synthetic, orsynthetic origin which, by virtue of its origin or manipulation, 1) isnot associated with all or a portion of a polynucleotide with which itis associated in nature; 2) is linked to a polynucleotide other thanthat to which it is linked in nature; or 3) does not occur in nature.

Therefore, recombinant nucleic acids comprising sequences otherwise notnaturally occurring are provided by this invention. Although thewild-type sequence may be employed, it will often be altered, e.g., bydeletion, substitution or insertion.

A “recombinant nucleic acid” is a nucleic acid that is not naturallyoccurring, or which is made by the artificial combination of twootherwise separated segments of sequence. This artificial combination isoften accomplished by either chemical syntheses means, or by theartificial manipulation of isolated segments of nucleic acids, bygenetic engineering techniques. Such is usually done to replace a codonwith a redundant codon encoding the same or a conservative amino acid,while typically introducing or removing a sequence recognition site.Alternatively, it is performed to join together nucleic acid segments ofdesired functions to generate a desired combination of functions. cDNAor genomic libraries of various types may be screened as natural sourcesof the nucleic acids of the present invention, or such nucleic acids maybe provided by amplification of sequences resident in genomic DNA orother natural sources, e.g., by PCR. The choice of cDNA librariesnormally corresponds to a tissue source that is abundant in mRNA for thedesired proteins. Phage libraries are normally preferred, but othertypes of libraries may be used. Clones of a library are spread ontoplates, transferred to a substrate for screening, denatured and probedfor the presence of desired sequences.

The nucleic acid sequences used in this invention will usually compriseat least about five codons (15 nucleotides), more usually at least about7-15 codons, and most preferably, at least about 35 codons. This numberof nucleotides is usually about the minimal length required for asuccessful HLS-5 fragment that is still capable of modulatingtranscription factors as described herein.

Techniques for nucleic acid manipulation are described generally, forexample, in Sambrook et al., 1989, supra or Ausubel et al., 1992,Current Protocols in Molecular Biology. Reagents useful in applying suchtechniques, such as restriction enzymes and the like, are widely knownin the art and commercially available from such vendors as New EnglandBioLabs, Boehringer Mannheim, Amersham, Promega Biotec, US Biochemicals,New England Nuclear and a number of other sources. The recombinantnucleic acid sequences used to produce fusion proteins of the presentinvention may be derived from natural or synthetic sequences. Manynatural gene sequences are obtainable from various cDNA or from genomiclibraries using appropriate probes. See, GenBank, National Institutes ofHealth.

As used herein, the term “HLS-5 gene sequence” refers to thedouble-stranded DNA comprising the gene sequence or region, as well aseither of the single-stranded DNAs comprising the gene sequence orregion (i.e. either of the coding and non-coding strands).

As used herein, a “portion” of the HLS-5 gene sequence or region isdefined as having a minimal size of at least about eight nucleotides, orpreferably about 15 nucleotides, or more preferably at least about 25nucleotides, and may have a minimal size of at least about 40nucleotides.

HLS-5 polynucleotide or fragments thereof may be obtained via any knownmolecular technique. PCR is one such technique that may be used toobtain HLS-5 gene sequences. This technique may amplify, for example,DNA or RNA, including messenger RNA, wherein DNA or RNA may be singlestranded or double stranded. In the event that RNA is to be used as atemplate, enzymes, and/or conditions optimal for reverse transcribingthe template to DNA would be utilized. In addition, a DNA-RNA hybridthat contains one strand of each may be utilized. A mixture of nucleicacids may also be employed, or the nucleic acids produced in a previousamplification reaction described herein, using the same or differentprimers may be so utilise.

The specific nucleic acid sequence to be amplified, i.e., the HLS-5 genesequence, may be a fraction of a larger molecule or can be presentinitially as a discrete molecule, so that the specific sequenceconstitutes the entire nucleic acid. It is not necessary that thesequence to be amplified is present initially in a pure form; it may bea minor fraction of a complex mixture, such as contained in whole humanDNA.

DNA utilized herein may be extracted from a body sample, such as blood,tissue material and the like by a variety of techniques such as thatdescribed by Maniatis et al. 1982, supra. If the extracted sample hasnot been purified, it may be treated before amplification with an amountof a reagent effective to open the cells, or animal cell membranes ofthe sample, and to expose and/or separate the strand(s) of the nucleicacid(s). This lysing and nucleic acid denaturing step to expose andseparate the strands will allow amplification to occur much morereadily.

The deoxyribonucleotide triphosphates dATP, dCTP, dGTP and dTTP areadded to the synthesis mixture, either separately or together with theprimers; in adequate amounts and the resulting solution is heated toabout 90°-100° C. from about 1 to 10 minutes, preferably from 1 to 4minutes. After this heating period, the solution is allowed to cool,which is preferable for the primer hybridization. To the cooled mixtureis added an appropriate agent for effecting the primer extensionreaction (called herein “agent for polymerization”), and the reaction isallowed to occur under conditions known in the art. The agent forpolymerization may also be added together with the other reagents if itis heat stable. This synthesis (or amplification) reaction may occur atroom temperature up to a temperature above which the agent forpolymerization no longer functions.

Thus, for example, if DNA polymerase is used as the agent, thetemperature is generally no greater than about 40° C. Most convenientlythe reaction occurs at room temperature.

The agent for polymerisation may be any compound or system which willfunction to accomplish the synthesis of primer extension products,including enzymes.

Suitable enzymes for this purpose include, for example, E. coli DNApolymerase I, Klenow fragment of E. coli DNA polymerase, polymerasemuteins, reverse transcriptase, other enzymes, including heat-stableenzymes (i.e., those enzymes which perform primer extension after beingsubjected to temperatures sufficiently elevated to cause denaturation),such as Taq polymerase. Suitable enzyme will facilitate combination ofthe nucleotides in the proper manner to form the primer extensionproducts that are complementary to each HLS-5 gene sequence nucleic acidstrand. Generally, the synthesis will be initiated at the 3′ end of eachprimer and proceed in the 5′ direction along the template strand, untilsynthesis terminates, producing molecules of different lengths.

The newly synthesised HLS-5 strand and its complementary nucleic acidstrand will form a double-stranded molecule under hybridizing conditionsdescribed above and this hybrid is used in subsequent steps of theprocess. In the next step, the newly synthesized HLS-5 double-strandedmolecule is subjected to denaturing conditions using any of theprocedures described above to provide single-stranded molecules.

The steps of denaturing, annealing, and extension product synthesis canbe repeated as often as needed to amplify the target polymorphic genesequence nucleic acid sequence to the extent necessary for detection.The amount of the specific nucleic acid sequence produced willaccumulate in an exponential fashion. Amplification is described in“PCR. A Practical Approach”, ILR Press, Eds. McPherson et al., 1992.

Sequences amplified by the methods of the invention can be furtherevaluated, detected, cloned, sequenced, and the like, either in solutionor after binding to a solid support, by any method usually applied tothe detection of a specific DNA sequence such as PCR, oligomerrestriction (Saiki et al., 1985, Bio/Technology, 3: 1008-1012),allele-specific oligonucleotide (ASO) probe analysis (Conner et al.,1983, Proc. Natl. Acad. Sci. USA., 80: 278), oligonucleotide ligationassays (OLAs) (Landgren et al., 1988, Science, 241: 1007) and the like.Molecular techniques for DNA analysis have been reviewed (Landgren etal., 1988, Science, 242: 229-237).

Methods of obtaining HLS-5 polynucleotides of the present inventioninclude PCR, as described herein and as commonly used by those ofordinary skill in the art. Alternative methods of amplification havebeen described and can also be employed as long as the HLS 5 genesequence amplified by PCR using primers of the invention is similarlyamplified by the alternative means. Such alternative amplificationsystems include but are not limited to self-sustained sequencereplication, which begins with a short sequence of RNA of interest and aT7 promoter. Reverse transcriptase copies the RNA into cDNA and degradesthe RNA, followed by reverse transcriptase polymerizing a second strandof DNA. Another nucleic acid amplification technique is nucleic acidsequence-based amplification (NASBA) which uses reverse transcriptionand T7 RNA polymerase and incorporates two primers to target its cyclingscheme. NASBA can begin with either DNA or RNA and finish with either,and amplifies to 108 copies within 60 to 90 minutes.

Alternatively, HLS-5 polynucleotides can be amplified by ligationactivated transcription (LAT). LAT works from a single-stranded templatewith a single primer that is partially single-stranded and partiallydouble-stranded. Amplification is initiated by ligating a cDNA to thepromoter oligonucleotide and within a few hours, amplification is 108 to109 fold. The QB replicase system can be utilized by attaching an RNAsequence called MDV-1 to RNA complementary to a DNA sequence ofinterest. Upon mixing with a sample, the hybrid RNA finds its complementamong the specimen's mRNAs and binds, activating the replicase to copythe tag-along sequence of interest. Another nucleic acid amplificationtechnique, ligase chain reaction (LCR), works by using two differentlylabelled halves of a sequence of interest that are covalently bonded byligase in the presence of the contiguous sequence in a sample, forming anew target. The repair chain reaction (RCR) nucleic acid amplificationtechnique uses two complementary and target-specific oligonucleotideprobe pairs, thermostable polymerase and ligase, and DNA nucleotides togeometrically amplify targeted sequences. A 2-base gap separates theoligonucleotide probe pairs, and the RCR fills and joins the gap,mimicking normal DNA repair. Nucleic acid amplification by stranddisplacement activation (SDA) utilizes a short primer containing arecognition site for Hinc II with short overhang on the 5′ end thatbinds to target DNA. A DNA polymerase fills in the part of the primeropposite the overhang with sulphur-containing adenine analogs. Hinc IIis added but only cuts the unmodified DNA strand. A DNA polymerase thatlacks 5′ exonuclease activity enters at the site of the nick and beginsto polymerize, displacing the initial primer strand downstream andbuilding a new one which serves as more primer. SDA produces greaterthan 107-fold amplification in 2 hours at 37° C. Unlike PCR and LCR, SDAdoes not require instrumented temperature cycling. Another amplificationsystem useful in the method of the invention is the QB Replicase System.Although PCR is the preferred method of amplification if the invention,these other methods can also be used to amplify the HLS-5 gene sequenceas described in the method of the invention.

Large amounts of the HLS-5 polynucleotides of the present invention mayalso be produced by replication in a suitable host cell. Natural orsynthetic polynucleotide fragments coding for a desired fragment will beincorporated into recombinant polynucleotide constructs, usually DNAconstructs, capable of introduction into and replication in aprokaryotic or eukaryotic cell. Usually the polynucleotide constructswill be suitable for replication in a unicellular host, such as yeast orbacteria, but may also be intended for introduction to (with and withoutintegration within the genome) cultured mammalian or plant or othereukaryotic cell lines.

A double-stranded fragment may be obtained from the single-strandedproduct of chemical synthesis either by synthesizing the complementarystrand and annealing the strands together under appropriate conditionsor by adding the complementary strand using DNA polymerase with anappropriate primer sequence.

HLS-5 polynucleotides of the invention may be incorporated into arecombinant replicable vector for introduction into a prokaryotic oreukaryotic host. Such vectors may typically comprise a replicationsystem recognized by the host, including the intended polynucleotidefragment encoding the desired polypeptide, and will preferably alsoinclude transcription and translational initiation regulatory sequencesoperably linked to the polypeptide encoding segment. Expression vectorsmay include, for example, an origin of replication or autonomouslyreplicating sequence (ARS) and expression control sequences, a promoter,an enhancer and necessary processing information sites, such asribosome-binding sites, RNA splice sites, polyadenylation sites,transcriptional terminator sequences, and mRNA stabilizing sequences.Secretion signals may also be included where appropriate, whether from anative HLS-5 protein or from other receptors or from secretedpolypeptides of the same or related species, which allow the protein tocross and/or lodge in cell membranes, and thus attain its functionaltopology, or be secreted from the cell. Such vectors may be prepared bymeans of standard recombinant techniques well known in the art anddiscussed, for example, in Sambrook et al., 1989 supra or Ausubel et al.1992 supra.

An appropriate promoter and other necessary vector sequences will beselected so as to be functional in the host, and may include, whenappropriate, those naturally associated with HLS-5 genes. Examples ofworkable combinations of cell lines and expression vectors are describedin Sambrook et al., 1989 supra or Ausubel et al., 1992. Many usefulvectors are known in the art and may be obtained from such vendors asStratagene, New England Biolabs, Promega, Biotech, and others. Promoterssuch as the trp, lac and phage promoters, tRNA promoters and glycolyticenzyme promoters may be used in prokaryotic hosts.

Useful yeast promoters include promoter regions for metallothionein,phosphoglycerate kinase or other glycolytic enzymes such as enolaseorglyceraldehyde-3-phosphate dehydrogenase, enzymes responsible formaltose and galactose utilization, and others. Vectors and promoterssuitable for use in yeast expression are further described in Hitzemanet al., 1983, Science, 219, pages 620-625.

Appropriate non-native mammalian promoters might include the early andlate promoters from SV40 or promoters derived from murine Moloneyleukemia virus, mouse tumour virus, avian sarcoma viruses, adenovirus11, bovine papilloma virus or polyoma. In addition, the construct may bejoined to an amplifiable gene (e.g., DHFR) so that multiple copies ofthe gene may be made.

While such expression vectors may replicate autonomously, they may alsoreplicate by being inserted into the genome of the host cell, by methodswell known in the art.

Expression and cloning vectors will likely contain a selectable marker,a gene encoding a protein necessary for survival or growth of a hostcell transformed with the vector. The presence of this gene ensuresgrowth of only those host cells that express the inserts. Typicalselection genes encode proteins that a) confer resistance to antibioticsor other toxic substances, e.g. ampicillin, neomycin, methotrexate,etc.; b) complement auxotrophic deficiencies, or c) supply criticalnutrients not available from complex media, e.g., the gene encodingD-alanine racemase for Bacilli. The choice of the proper selectablemarker will depend on the host cell, and appropriate markers fordifferent hosts are well known in the art.

The vectors containing the nucleic acids of interest can be transcribedin vitro, and the resulting RNA introduced into the host cell bywell-known methods, e.g., by injection, or the vectors can be introduceddirectly into host cells by methods well known in the art, which varydepending on the type of cellular host, including electroporation;transfection employing calcium chloride, rubidium chloride, calciumphosphate, DEAE-dextran, or other substances; microprojectilebombardment; lipofection; infection (where the vector is an infectiousagent, such as a retroviral genome); and other methods. The introductionof the polynucleotides into the host cell by any method known in theart, including, inter alia, those described above, will be referred toherein as “transformation”. The cells into which have been introducednucleic acids described above are meant to also include the progeny ofsuch cells.

Thus the present invention provides host cells transformed ortransfected with a nucleic acid molecule of the invention. Preferredhost cells include bacteria, yeast, mammalian cells, plant cells, insectcells, and human cells.

Illustratively, such host cells are selected from the group consistingof E. coli, Pseudomonas, Bacillus, Streptomyces, yeast, CHO, R1.1, B-W,L-M, COS 1, COS 7, BSC1, BSC40, BMT10, and Sf9 cells.

Large quantities of the HLS-5 polypeptides of the present invention maybe prepared by expressing the HLS-5 polynucleotides or portions thereofin vectors or other expression vehicles in compatible prokaryotic oreukaryotic host cells. The most commonly used prokaryotic hosts arestrains of Escherichia coli, although other prokaryotes, such asBacillus subtilis or Pseudomonas may also be used.

Also provided are mammalian cells containing an HLS-5 polypeptideencoding DNA sequence and modified in vitro to permit higher expressionof HLS-5 polypeptide by means of a homologous recombinational eventconsisting of inserting an expression regulatory sequence in functionalproximity to the HLS-5 polypeptide encoding sequence. The expressionregulatory sequence can be an HLS-5 polypeptide expression or not andcan replace a mutant HLS-5 polypeptide regulatory sequence in the cell.

Thus, the present invention also provides methods for preparing an HLS-5polypeptide comprising: (a) culturing a cell as described above underconditions that provide for expression of the HLS-5 polypeptide; and (b)recovering the expressed HLS-5 polypeptide. This procedure can also beaccompanied by the steps of: (c) chromatographing the polypeptide usingany suitable means known in the art; and (d) purifying the polypeptideby for example gel filtration.

Mammalian or other eukaryotic host cells, such as those of yeast,filamentous fungi, plant, insect, or amphibian or avian species, mayalso be useful for production of the proteins of the present invention.Propagation of mammalian cells in culture is per se well known. Examplesof commonly used mammalian host cell lines are VERO and HeLa cells,Chinese hamster ovary (CHO) cells, and W138, BHK, and COS cell lines,although it will be appreciated by the skilled practitioner that othercell lines may be appropriate, e.g., to provide higher expression,desirable glycosylation patterns, or other features.

Clones are selected by using markers depending on the mode of the vectorconstruction. The marker may be on the same or a different DNA molecule,preferably the same DNA molecule. In prokaryotic hosts, the transformantmay be selected, e.g., by resistance to ampicillin, tetracycline orother antibiotics.

Production of a particular product based on temperature sensitivity mayalso serve as an appropriate marker.

Prokaryotic or eukaryotic cells transformed with the polynucleotides ofthe present invention will be useful not only for the production of thenucleic acids and polypeptides of the present invention.

In some embodiments the “transcription factor modulator” is a compoundor composition capable of regulating the endogenous levels of HLS-5and/or HLS-5 activity. In some embodiments, these compounds andcompositions are termed “control agents”. Control agents useful in thepresent invention may be located by standard assays. Protocols forcarrying out such assays are well known to those of skill in the art andneed not be described in great detail here. The term “control agent” or“drug candidate” or “modulator” or “modifying agent” or grammaticalequivalents as used herein describes any molecule, eg., protein,oligopeptide, small organic molecule, polysaccharide, polynucleotide,etc., to be tested for the capacity to directly or indirectly controlthe expression of HLS-5 e.g., a nucleic acid or protein sequence. Insome embodiments, the control agents will reduce the endogenous amountof HLS-5, while in other embodiments, the control agents will increaseendogenous amount of HLS-5.

The term “drug candidates” encompass numerous chemical classes, thoughtypically they are organic molecules, preferably small organic compoundshaving a molecular weight of more than 100 and less than about 2,500daltons. Preferred small molecules are less than 2000, or less than 1500or less than 1000 or less than 500 Daltons. Candidate control agentscomprise functional groups necessary for structural interaction withproteins, particularly hydrogen bonding, and typically include at leastan amine, barbonyl, hydroxyl or carboxyl group, preferably at least twoof the functional chemical groups. The candidate control agents oftencomprise cyclical carbon or heterocyclic structures and/or aromatic orpolyaromatic structures substituted with one or more of the abovefunctional groups. Candidate control agents are also found amongbiomolecules including peptides, saccharides, fatty acids, steroids,purines, pyrimidines, derivatives, structural analogs or combinationsthereof. Particularly preferred are peptides.

The term “regulating” as used herein with reference to the endogenouslevels of HLS-5 refers to the ability of the compound or composition toincrease or decrease the endogenous levels of HLS-5 and/or HLS-5activity as compared to the wild-type and/or normal levels. In someembodiments, control agents of the present invention that are capable ofregulating the endogenous levels of HLS-5 and/or HLS-5 activity can beinitially identified using in vitro cell based assays. For example, asystem such as Chroma-Luc™, Luc™ or GFP™ reporter genes can be providedin multiple different cloning vector formats. The Basic vector versionsare general-purpose reporter vectors based on the design, for example ofthe pGL3-Basic Vector, which lacks eukaryotic promoter and enhancersequences, allowing cloning putative regulatory sequences, such as theHLS-5 promoter at the 5′ end of the reporter gene. Expression ofluciferase, or any reporter gene, activity in cells transfected withthis “pGL3-Promoter Vector” depends on elements or compounds being ableto induce directly or indirectly the expression through the clonedpromoter of interest, such as the HLS5 promoter. In addition to thebasic vector configuration, other systems such as the Chroma-Luc™ genesare available in a vector configuration containing an SV40 promoter andSV40 enhancer, similar to the pGL3-Control Vector. The presence of theSV40 promoter and enhancer sequences result in strong expression of luc+in many types of mammalian cells. Thus this technology and any othervector modification is suitable for rapid quantitation in multiwellplates and in high-throughput applications to assay for compounds whichare potentially capable of modifying the HLS-5 protein expression bymeasuring the reporter gene downstream of the HLS-5 promoter. Theseidentified compounds can than be tested in cells with the endogenousHLS-5 promoter and protein expression assayed by such methods as WesternBlots. In general, any luminometer capable of measuring filteredluminescence should be able to perform dual-colour assays and anyscientist skilled in the art can reproduce these assays.

Once the transcription factor modulators eg HLS-polypeptide, HLS-5polynucleotide in appropriate vector or compound/composition capable ofregulating the endogenous levels of HLS-5 and/or HLS-5 activity, havebeen obtained they are then administered to a subject in need thereof inorder to modulate transcription factor activity. Thus, in someembodiments, the present invention provides a method of treating asubject suffering from a “transcription factor-associated disorder” i.e.a disorder which is affected, by, controlled by or exacerbated bytranscription factor activity and therefore, the step of administrationassists in the treatment of the condition.

Generally, the terms “treating,” “treatment” and the like are usedherein to mean affecting a subject e.g. human individual or animal,their tissue or cells to obtain a desired pharmacological and/orphysiological effect. The effect may be prophylactic in terms ofcompletely or partially preventing the transcription factor-associateddisorder or sign or symptom thereof, and/or may be therapeutic in termsof a partial or complete cure of the transcription factor-associateddisorder. “Treating” as used herein covers any treatment of, orprevention of a condition associated with or exacerbated bytranscription factor activity in a vertebrate, a mammal, particularly ahuman, and includes: (a) preventing the condition from occurring in asubject that may be predisposed to the transcription factor-associateddisorder, but has not yet been diagnosed as having it; (b) inhibitingthe transcription factor-associated disorder, i.e., arresting itsdevelopment; or (c) relieving or ameliorating the condition, i.e., causeregression of the symptoms.

The term “subject” as used herein refers to an animal subject in whichthe modulation of transcription factor activity is desirable. Thesubject may be a human, or may be a domestic, companion or zoo animal.While it is particularly contemplated that the transcription factormodulator of the invention is suitable for use in medical treatment ofhumans, it is also applicable to veterinary treatment, includingtreatment of companion animals such as dogs and cats, and domesticanimals such as horses, cattle and sheep, or zoo animals such asnon-human primates, felids, canids, bovids, and ungulates.

The transcription factor modulator can be administered in various forms,depending on the condition to be treated and the age, condition and bodyweight of the subject, as is well known in the art. For example, wherethe transcription factor modulator is to be administered orally, it maybe formulated as tablets, capsules, granules, powders or syrups; or forparenteral administration, it may be formulated as injections(intravenous, intramuscular or subcutaneous), drop infusion preparationsor suppositories. For application by the ophthalmic mucous membraneroute, it may be formulated as eye drops or eye ointments. Theseformulations can be prepared by conventional means, and, if desired, theactive ingredient may be mixed with any conventional additive, such asan excipient, a binder, a disintegrating agent, a lubricant, acorrigent, a solubilizing agent, a suspension aid, an emulsifying agentor a coating agent. Although the dosage will vary depending on thesymptoms, age and body weight of the subject, the nature and severity ofthe condition to be treated or prevented, the route of administrationand the form of the transcription factor modulator, in general, a dailydosage of from 0.01 to 2000 mg of the transcription factor modulators isrecommended for an adult human subject, and this may be administered ina single dose or in divided doses.

An effective time for administering the transcription factor modulatorneeds to be identified. This can be accomplished by routine experiments.For example, in animals, the control of transcription factor activity bythe transcription factor modulator can be assessed by administering thetranscription factor modulator at a particular time of day and measuringthe effect of the administration (if any) by measuring one or moreindices associated with transcription factor activity, and comparing thepost-treatment values of these indices to the values of the same indicesprior to treatment.

The precise time of administration and/or amount of transcription factormodulator that will yield the most effective results in terms ofefficacy of treatment in a given subject will depend upon the activity,pharmacokinetics, and bioavailability of a particular transcriptionfactor modulator, physiological condition of the subject (including age,sex, disease type and stage, general physical condition, responsivenessto a given dosage and type of medication), route of administration, etc.However, the above guidelines can be used as the basis for fine-tuningthe treatment, eg., determining the optimum time and/or amount ofadministration, which will require no more than routine experimentationconsisting of monitoring the subject and adjusting the dosage and/ortiming.

The phrases “pharmaceutically-effective amount” and“therapeutically-effective amount” as used herein means that amount of atranscription factor modulator, which is effective for producing somedesired therapeutic effect, for example, the inhibition of transcriptionfactor activity of a protein at a reasonable benefit/risk ratioapplicable to any medical treatment.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose transcription factor modulators, materials, compositions, and/ordosage forms which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of human beings and animalswithout excessive toxicity, irritation, allergic response, or otherproblem or complication, commensurate with a reasonable benefit/riskratio.

The phrase “pharmaceutically-acceptable carrier” as used herein means apharmaceutically-acceptable material, composition or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulatingmaterial, involved in carrying or transporting the transcription factormodulators from one organ, or portion of the body, to another organ, orportion of the body. Each carrier must be “acceptable” in the sense ofbeing compatible with the other ingredients of the formulation and notinjurious to the subject. Some examples of materials which can serve aspharmaceutically-acceptable carriers include: (1) sugars, such aslactose, glucose and sucrose; (2) starches, such as corn starch andpotato starch; (3) cellulose, and its derivatives, such as sodiumcarboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4)powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients,such as cocoa butter and suppository waxes; (9) oils, such as peanutoil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil andsoybean oil; (10) glycols, such as propylene glycol; (11) polyols, suchas glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters,such as ethyl oleate and ethyl laurate; (13) agar; (14) bufferingagents, such as magnesium hydroxide and aluminium hydroxide; (15)alginic acid, (16) pyrogen-free water; (17) isotonic saline; (18)Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions;and (21) other non-toxic compatible substances employed inpharmaceutical formulations.

Wetting agents, emulsifiers and lubricants, such as sodium laurylsulfate and magnesium stearate, as well as colouring agents, releaseagents, coating agents, sweetening, flavouring and perfuming agents,preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically-acceptable antioxidants include: (1) watersoluble antioxidants, such as ascorbic acid, cysteine hydrochloride,sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2)oil-soluble antioxidants, such as ascorbyl palmitate, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin; propylgallate, alpha-tocopherol, and the like; and (3) metal chelating agents,such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol,tartaric acid, phosphoric acid, and the like.

Formulations useful in the methods of the present invention includethose suitable for oral, nasal, topical (including buccal andsublingual), rectal, vaginal, aerosol and/or parenteral administration.The formulations may conveniently be presented in unit dosage form andmay be prepared by any methods well known in the art of pharmacy. Theamount of active ingredient which can be combined with a carriermaterial to produce a single dosage form will vary depending upon thehost being treated, the particular mode of administration. The amount ofactive ingredient which can be combined with a carrier material toproduce a single dosage form will generally be that amount of thecompound which produces a therapeutic effect. Generally, out of onehundred percent, this amount will range from about 1 percent to aboutninety-nine percent of active ingredient, preferably from about 5percent to about 70 percent, most preferably from about 10 percent toabout 30 percent.

Methods of preparing these formulations or compositions include the stepof bringing into association a transcription factor modulator(s) withthe carrier and, optionally, one or more accessory ingredients. Ingeneral, the formulations are prepared by uniformly and intimatelybringing into association a transcription factor modulator with liquidcarriers, or finely divided solid carriers, or both, and then, ifnecessary, shaping the product.

Formulations suitable for oral administration may be in the form ofcapsules, cachets, pills, tablets, lozenges (using a flavoured basis,usually sucrose and acacia or tragacanth), powders, granules, or as asolution or a suspension in an aqueous or non-aqueous liquid, or as anoil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup,or as pastilles (using an inert base, such as gelatine and glycerine, orsucrose and acacia) and/or as mouth washes and the like, each containinga predetermined amount of a transcription factor modulator(s) as anactive ingredient. A compound may also be administered as a bolus,electuary or paste.

In solid dosage forms for oral administration (capsules, tablets, pills,powders, granules and the like), the active ingredient is mixed with oneor more pharmaceutically-acceptable carriers, such as sodium citrate ordicalcium phosphate, and/or any of the following: (1) fillers orextenders, such as starches, lactose, sucrose, glucose, mannitol, and/orsilicic acid; (2) binders, such as, for example, carboxymethylcellulose,alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3)humectants, such as glycerol; (4) disintegrating agents, such asagar-agar, calcium carbonate, potato or tapioca starch, alginic acid,certain silicates, and sodium carbonate; (5) solution retarding agents,such as paraffin; (6) absorption accelerators, such as quaternaryammonium compounds; (7) wetting agents, such as, for example, acetylalcohol and glycerol monostearate; (8) absorbents, such as kaolin andbentonite clay; (9) lubricants, such a talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate, andmixtures thereof; and (10) colouring agents. In the case of capsules,tablets and pills, the pharmaceutical compositions may also comprisebuffering agents. Solid compositions of a similar type may also beemployed as fillers in soft and hard-filled gelatine capsules using suchexcipients as lactose or milk sugars, as well as high molecular weightpolyethylene glycols and the like.

A tablet may be made by compression or moulding, optionally with one ormore accessory ingredients. Compressed tablets may be prepared usingbinder (for example, gelatine or hydroxypropylmethyl cellulose),lubricant, inert diluent, preservative, disintegrant (for example,sodium starch glycolate or cross-linked sodium carboxymethyl cellulose),surface-active or dispersing agent. Moulded tablets may be made bymoulding in a suitable machine a mixture of the powdered peptide orpeptidomimetic moistened with an inert liquid diluent.

Tablets, and other solid dosage forms, such as dragees, capsules, pillsand granules, may optionally be scored or prepared with coatings andshells, such as enteric coatings and other coatings well known in thepharmaceutical-formulating art. They may also be formulated so as toprovide slow or controlled release of the active ingredient thereinusing, for example, hydroxypropylmethyl cellulose in varying proportionsto provide the desired release profile, other polymer matrices,liposomes and/or microspheres. They may be sterilized by, for example,filtration through a bacteria-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved in sterile water, or some other sterile injectable mediumimmediately before use. These compositions may also optionally containopacifying agents and may be of a composition that they release theactive ingredient(s) only, or preferentially, in a certain portion ofthe gastrointestinal tract, optionally, in a delayed manner. Examples ofembedding compositions which can be used include polymeric substancesand waxes. The active ingredient can also be in micro-encapsulated form,if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups andelixirs. In addition to the active ingredient, the liquid dosage formsmay contain inert diluents commonly used in the art, such as, forexample, water or other solvents, solubilizing agents and emulsifiers,such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils (in particular, cottonseed, groundnut, corn, germ, olive,castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavouring, colouring, perfuming and preservative agents.

Suspensions, in addition to the active transcription factor modulator(s)may contain suspending agents as, for example, ethoxylated isostearylalcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystallinecellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth,and mixtures thereof.

Dosage forms for the topical or transdermal administration of atranscription factor modulator(s) include powders, sprays, ointments,pastes, creams, lotions, gels, solutions, patches and inhalants. Theactive component may be mixed under sterile conditions with apharmaceutically-acceptable carrier, and with any preservatives,buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, in addition totranscription factor modulator(s), excipients, such as animal andvegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycols, silicones, bentonites, silicic acid,talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a transcription factormodulator(s), excipients such as lactose, talc, silicic acid, aluminiumhydroxide, calcium silicates and polyamide powder, or mixtures of thesesubstances. Sprays can additionally contain customary propellants, suchas chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons,such as butane and propane.

The transcription factor modulator(s) can be alternatively administeredby aerosol. This is accomplished by preparing an aqueous aerosol,liposomal preparation or solid particles containing the compound. Anon-aqueous (e.g., fluorocarbon propellant) suspension could be used.Sonic nebulizers are preferred because they minimize exposing the agentto shear, which can result in degradation of the compound.

Ordinarily, an aqueous aerosol is made by formulating an aqueoussolution or suspension of the agent together with conventionalpharmaceutically acceptable carriers and stabilizers. The carriers andstabilizes vary with the requirements of the particular compound, buttypically include non-ionic surfactants (Tweens, Pluronics, orpolyethylene glycol), innocuous proteins like serum albumin, sorbitanesters, oleic acid, lecithin, amino acids such as glycine, buffers,salts, sugars or sugar alcohols. Aerosols generally are prepared fromisotonic solutions.

Transdermal patches have the added advantage of providing controlleddelivery of a transcription factor modulator(s) to the body. Such dosageforms can be made by dissolving or dispersing the agent in the propermedium. Absorption enhancers can also be used to increase the flux ofthe peptidomimetic across the skin. The rate of such flux can becontrolled by either providing a rate controlling membrane or dispersingthe peptidomimetic in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like,are also contemplated as being within the scope of this invention.

Pharmaceutical compositions of this invention suitable for parenteraladministration comprise one or more transcription factor modulator(s) incombination with one or more pharmaceutically-acceptable sterileisotonic aqueous or non-aqueous solutions, dispersions, suspensions oremulsions, or sterile powders which may be reconstituted into sterileinjectable solutions or dispersions just prior to use, which may containantioxidants, buffers, bacteriostats, solutes which render theformulation isotonic with the blood of the intended recipient orsuspending or thickening agents.

Examples of suitable aqueous and non-aqueous carriers which may beemployed in the pharmaceutical compositions of the invention includewater, ethanol, polyols (such as glycerol, propylene glycol,polyethylene glycol, and the like), and suitable mixtures thereof,vegetable oils, such as olive oil, and injectable organic esters, suchas ethyl oleate. Proper fluidity can be maintained, for example, by theuse of coating materials, such as lecithin, by the maintenance of therequired. particle size in the case of dispersions, and by the use ofsurfactants.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofthe action of microorganisms may be ensured by the inclusion of variousanti-bacterial and anti-fungal agents, for example, paraben,chlorobutanol, phenol sorbic-acid, and the like. It may also bedesirable to include isotonic agents, such as sugars, sodium chloride,and the like into the compositions. In addition, prolonged absorption ofthe injectable pharmaceutical form may be brought about by the inclusionof agents which delay absorption such as aluminium monostearate andgelatine.

In some cases, in order to prolong the effect of a transcription factormodulator, it is desirable to slow the absorption of the agent fromsubcutaneous or intramuscular injection. This may be accomplished by theuse of a liquid suspension of crystalline or amorphous material havingpoor water solubility. The rate of absorption of the drug then dependsupon its rate of dissolution which, in turn, may depend upon crystalsize and crystalline form. Alternatively, delayed absorption of aparenterally-administered agent form is accomplished by dissolving orsuspending the modulator in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices oftranscription factor modulator(s) in biodegradable polymers such aspolylactide-polyglycolide. Depending on the ratio of modulator topolymer, and the nature of the particular polymer employed, the rate ofmodulator release can be controlled. Examples of other biodegradablepolymers include poly(orthoesters) and poly(anhydrides). Depotinjectable formulations are also prepared by entrapping the modulator inliposomes or microemulsions which are compatible with body tissue.

The phrases “parenteral administration” and “administered parenterally”as used herein means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular,subarachnoid, intraspinal and intrasternal injection and infusion.

The phrases “systemic administration,” “administered systemically,”“peripheral administration” and “administered peripherally” as usedherein mean the administration of a transcription factor modulator otherthan directly into the central nervous system, such that it enters thesubjects system and, thus, is subject to metabolism and other likeprocesses, for example, subcutaneous administration.

Another aspect of the invention provides a conjoint therapy wherein oneor more other therapeutic agents are administered with the transcriptionfactor modulator. Such conjoint treatment may be achieved by way of thesimultaneous, sequential or separate dosing of the individual componentsof the treatment.

In some embodiments, a transcription factor modulator is conjointlyadministered with anti-cancer agents or other therapeutic agents knownto be useful in the treatment of the condition being treated. Forexample, gene therapy using HLS-5 expression vector together with ananti-cancer agent.

In another illustrative embodiment, the subject control agents can beconjointly administered with a transcription factor agonist orantagonist.

As described supra, in some embodiments the HLS-polynucleotides andvectors of the invention for in vivo delivery and expression. Thisapproach has also been called “gene therapy” and as such is well knownin the art. Gene therapy protocols may involve administering atherapeutically-effective amount of a HLS-5 polynucleotide vectorcapable of directing expression of the HLS-5 polypeptide to a subjecteither before, substantially contemporaneously, with, or after influenzavirus infection. Another approach that may be used alternatively or incombination with the foregoing is to isolate a population of cells,e.g., stem cells or immune system cells from a subject, optionallyexpand the cells in tissue culture, and administer a HLS-5polynucleotide vector capable of directing expression of HLS-5 to thecells in vitro. The cells may then be returned to the subject.Optionally, cells expressing the HLS-5 polynucleotides can be selectedin vitro prior to introducing them into the subject. In some embodimentsof the invention a population of cells, which may be cells from a cellline or from an individual who is not the subject, can be used. Methodsof isolating stem cells, immune system cells, etc., from a subject andreturning them to the subject are well known in the art. Such methodsare used, eg., for bone marrow transplant, peripheral blood stem celltransplant, etc., in patients undergoing chemotherapy.

In yet another approach, oral gene therapy may be used. For example,U.S. Pat. No. 6,248,720 describes methods and compositions whereby genesunder the control of promoters are protectively contained inmicroparticles and delivered to cells in operative form, therebyachieving non-invasive gene delivery. Following oral administration ofthe microparticles, the genes are taken up into the epithelial cells,including absorptive intestinal epithelial cells, taken up into gutassociated lymphoid tissue, and even transported to cells remote fromthe mucosal epithelium. As described therein, the microparticles candeliver the genes to sites remote from the mucosal epithelium, i.e. cancross the epithelial barrier and enter into general circulation, therebytransfecting cells at other locations.

As used herein, the term “condition” is interchangeably used with theterm “transcription factor-associated disorder”, which includes adisease, disorder, or condition, which is caused by or associated withthe function of a transcription factor in a cell. A transcriptionfactor-associated disorder includes a disease, disorder, or condition,which proceeds, directly or indirectly, via transcription factor-inducedgene transcription.

At present there are a number of conditions/disorders known to beaffected by aberrant transcription factor activity including, but notlimited to, cancer (e.g. aberrant cellular apoptosis), viral infection,and Crohn's disease. Thus, for example, a transcriptionfactor-associated disorder may be an NF-KB associated disorder, such as:(a) an ischemic disease, e.g., ischemic diseases of organs (e.g.,ischemic heart diseases such as myocardial infarction, acute heartfailure, chronic heart failure, ischemic brain diseases such as cerebralinfarction, and ischemic lung diseases such as pulmonary infarction),aggravation of the prognosis of organ transplantation or organ surgery(e.g., aggravation of the prognosis of heart transplantation, cardiacsurgery, kidney transplantation, renal surgery, liver transplantation,hepatic surgery, bone marrow transplantation, skin grafting, cornealtransplantation, and lung transplantation), reperfusion disorders, andpost-PTCA restenosis; (b) an inflammatory disease, e.g., nephritis,hepatitis, arthritis, acute renal failure, chronic renal failure, andarteriosclerosis; and (c) an autoimmune disease, e.g., rheumatism,multiple sclerosis, and Hashimoto's thyroiditis. An NF-KB containingtranscription factor modulator of the present invention is particularlysuited for the therapy and prophylaxis of reperfusion disorders inischemic diseases, aggravation of the prognosis of organ transplantationor organ surgery, post-PTCA restenosis, cancer metastasis and invasion,and cachexia such as weight loss following the onset of a cancer.

A transcription factor-associated disorder may also be anandrogen-associated disorder, i.e., a disease, disorder, or condition,which proceeds, directly or indirectly, via androgen receptor-inducedgene transcription. Androgen associated disorders include benignprostatic hypertrophy, male pattern baldness, acne, idiopathichirsutism, and Stein-Leventhal syndrome. Androgen associated disordersfurther include cancers whose growth is promoted by androgens egprostate cancer, ovarian cancer, bladder cancer, colon cancer, livercancer, endometrial cancer, pancreatic cancer, lung cancer, esophagealcancer, cancer of the larynx and breast cancer. Otherandrogen-associated disorders include androgen insensitivity syndromes,infertility, endometrial cancer, and X-linked spinal bulbar muscularatrophy (SMBA). Examples of partial androgen insensitivity syndromesinclude incomplete testicular feminization, Reifenstein syndrome, Lubssyndrome, Gilbert-Dreifus syndrome, and Rosewater syndrome.

A transcription factor-associated disorder may also be an estrogenreceptor-associated disorder, i.e., a disease, disorder, or condition,which proceeds, directly or indirectly, via estrogen receptor-inducedgene transcription. Examples of estrogen receptor-associated disordersinclude breast cancer, osteoporosis, endometriosis, cardiovasculardisease, hypercholesterolemia, prostatic hypertrophy, prostaticcarcinomas, obesity, hot flashes, skin effects, mood swings, memoryloss, menopausal syndromes, hair loss (alopecia), type-II diabetes,Alzheimer's disease, urinary incontinence, GI tract conditions,spermatogenesis, disorders associated with plasma lipid levels, acne,hirsutism, other solid cancers (such as colon, lung, ovarian, testis,melanoma, CNS, and renal), multiple myeloma, cataracts, lymphoma, andadverse reproductive effects associated with exposure to environmentalchemicals.

In other embodiments, the transcription associated disorder is adisorder associated with aberrant (abnormally increased or decreased)apoptotic processes. These include disorders associated with decreasedapoptotic processes, eg., cellular proliferative disorders or cellulardifferentiative disorders, eg., cancer, autoimmune disorders, orpsoriasis, and disorders associated with increased apoptosis, e.g.,degenerative disorders (including neurodegenerative disorders such asAlzheimer's Disease, amyotrophic lateral sclerosis (ALS), Parkinson'sdisease, Alzheimer's disease, ischemic brain injury, and Huntington'sdisease), Glaucoma, Age-related macular degeneration (AMD), peripheralneuropathy, stroke, depression, Diamond-Blackfan Anemia (DBA), FanconiAnemia (FA) Shwachman Diamond Syndrome (SDS), ischemic injury(myocardial infarction), and virus induced lymphocyte depletion (e.g.,associated with HIV/AIDS).

Examples of cellular proliferative and/or differentiative disordersinclude cancer, eg., carcinoma, sarcoma, metastatic disorders orhematopoietic neoplastic disorders, eg., leukaemia's. A metastatic tumorcan arise from a multitude of primary tumor types, including but notlimited to those of prostate, colon, lung, breast and liver origin.

As used herein, the terms “cancer,” “hyperproliferative,” and“neoplastic” refer to cells having the capacity for autonomous growth,i.e., an abnormal state or condition characterized by rapidlyproliferating cell growth. Hyperproliferative and neoplastic diseasestates may be categorized as pathologic, i.e., characterizing orconstituting a disease state, or may be categorized as non-pathologic,i.e., a deviation from normal but not associated with a disease state.The term is meant to include all types of cancerous growths or oncogenicprocesses, metastatic tissues or malignantly transformed cells, tissues,or organs, irrespective of histopathologic type or stage ofinvasiveness. “Pathologic hyperproliferative” cells occur in diseasestates characterized by malignant tumor growth. Examples ofnon-pathologic hyperproliferative cells include proliferation of cellsassociated with wound repair.

Additional examples of proliferative disorders include hematopoieticneoplastic disorders. As used herein, the term “hematopoietic neoplasticdisorders” includes diseases involving hyperplastic/neoplastic cells ofhematopoietic origin, eg., arising from myeloid, lymphoid or erythroidlineages, or precursor cells thereof. In some embodiments, the diseasesarise from poorly differentiated acute leukemias, e.g., erythroblasticleukemia and acute megakaryoblastic leukemia. Additional exemplarymyeloid disorders include, but are not limited to, acute promyeloidleukemia (APML), acute myelogenous leukemia (AML) and chronicmyelogenous leukemia (CML); lymphoid malignancies include, but are notlimited to acute lymphoblastic leukemia (ALL) which includes B-lineageALL and T-lineage ALL, chronic lymphocytic leukemia (CLL),prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) andWaldenstrom's macroglobulinemia (WM). Additional forms of malignantlymphomas include, but are not limited to non-Hodgkin lymphoma andvariants thereof, peripheral T cell lymphomas, adult T cellleukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), largegranular lymphocytic leukemia (LGF), Hodgkin's disease andReed-Sternberg disease.

Other examples of proliferative and/or differentiative disorders includeskin disorders. The skin disorder may involve the aberrant activity of acell or a group of cells or layers in the dermal, epidermal, orhypodermal layer, or an abnormality in the dermal-epidermal junction.

Examples of skin disorders include psoriasis, psoriatic arthritis,dermatitis (eczema), e.g., exfoliative dermatitis or atopic dermatitis,pityriasis rubra pilaris, pityriasis rosacea, parapsoriasis, pityriasislichenoiders, lichen planus, lichen nitidus, ichthyosiform dermatosis,keratodermas, dermatosis, alopecia greata, pyoderma gangrenosum,vitiligo, pemphigoid (e.g., ocular cicatricial pemphigoid or bullouspemphigoid), urticaria, prokeratosis, rheumatoid arthritis that involveshyperproliferation and inflammation of epithelial-related cells liningthe joint capsule; dermatitises such as atopic dermatitis, allergicdermatitis, seborrheic dermatitis or solar dermatitis; keratoses such asseborrheic keratosis, senile keratosis, actinic keratosis, photo-inducedkeratosis, and keratosis follicularis; acne vulgaris; keloids andprophylaxis against keloid formation; nevi; warts including verruca,condyloma or condyloma acuminatum, and human papilloma viral (HPV)infections such as venereal warts; leukoplakia; lichen planus; keratitisand viral infections

Thus, for example, a transcription factor-associated disorder may be anNF-KB associated disorder, such as: (a) an ischemic disease, e.g.,ischemic diseases of organs (e.g., ischemic heart diseases such asmyocardial infarction, acute heart failure, chronic heart failure,ischemic brain diseases such as cerebral infarction, and ischemic lungdiseases such as pulmonary infarction), aggravation of the prognosis oforgan transplantation or organ surgery (e.g., aggravation of theprognosis of heart transplantation, cardiac surgery, kidneytransplantation, renal surgery, liver transplantation, hepatic surgery,bone marrow transplantation, skin grafting, corneal transplantation, andlung transplantation), reperfusion disorders, and post-PTCA restenosis;(b) an inflammatory disease, e.g., nephritis, hepatitis, arthritis,acute renal failure, chronic renal failure, and arteriosclerosis; and(c) an autoimmune disease, e.g., rheumatism, multiple sclerosis, andHashimoto's thyroiditis. An NF-KB containing transcription factormodulator of the present invention is particularly suited for thetherapy and prophylaxis of reperfusion disorders in ischemic diseases,aggravation of the prognosis of organ transplantation or organ surgery,post-PTCA restenosis, cancer metastasis and invasion, and cachexia suchas weight loss following the onset of a cancer.

The present invention also provides assays that are suitable foridentifying substances that bind to HLS-5 polypeptides (reference towhich includes homologues, variants, derivatives and fragments asdescribed above). In addition, assays are provided that are suitable foridentifying substances that interfere with HLS-5 binding to cellularcomponents involved in sumoylation, for example proteins identified inyeast two-hybrid screens as interacting with HLS-5. Such assays aretypically in vitro. Assays are also provided that test the effects ofcandidate substances identified in preliminary in vitro assays on intactcells in whole cell assays.

For example, a substance that alters transcription factor activity as aresult of an interaction with HLS-5 polypeptides may do so in severalways. It may directly disrupt the binding of HLS-5 to a cellularcomponent of the cell cycle machinery by, for example, binding to HLS-5and masking or altering the site of interaction with the othercomponent. Candidate substances of this type may conveniently bepreliminarily screened by in vitro binding assays as, for example,described below and then tested, for example in a whole cell assay asdescribed below.

Methods to screen potential agents for their ability to disrupt ormoderate ubiquitin ligase expression and activity can be designed basedon its known and potential substrates. For example, candidate compoundscan be screened for their ability to modulate the interaction of anHLS-5 and Skp1, or the specific interactions of Skp2 with E2F-1, Skp2with Cks1, Skp2 with Cks1 and p27, or the FBP1/Cull/Skp1 complex withβ-catenin. In principle, many methods known to those of skill in theart, can be readily adapted in designed the assays of the presentinvention.

The screening assays of the present invention also encompasshigh-throughput screens and assays to identify modulators of HLS-5expression and activity. In accordance with this embodiment, the systemsdescribed below may be formulated into kits. To this end, cellsexpressing HLS-5 and components of the ubiquitin ligase complex and theubiquitination pathway, or cell lysates, thereof can be packaged in avariety of containers, e.g., vials, tubes, microtitre well plates,bottles, and the like. Other reagents can be included in separatecontainers and provided with the kit; e.g., positive control samples,negative control samples, buffers, cell culture media, etc.

The invention provides screening methodologies useful in theidentification of proteins and other compounds which bind to, orotherwise directly interact with, the HLS-5 genes and their geneproducts. Screening methodologies are well known in the art (see eg.,PCT International Publication No. WO 96/34099, published Oct. 31, 1996,which is incorporated by reference herein in its entirety). The proteinsand compounds include endogenous cellular components which interact withthe identified genes and proteins in vivo and which, therefore, mayprovide new targets for pharmaceutical and therapeutic interventions, aswell as recombinant, synthetic, and otherwise exogenous compounds whichmay have binding capacity and, therefore, may be candidates forpharmaceutical agents. Thus, in one series of embodiments, cell lysatesor tissue homogenates may be screened for proteins or other compoundswhich bind to one of the normal or mutant HLS-5 genes and HLS-5proteins.

Alternatively, any of a variety of exogenous compounds, both naturallyoccurring and/or synthetic (e.g., libraries of small molecules orpeptides), may be screened for binding capacity. All of these methodscomprise the step of mixing an HLS-5 protein or fragment with testcompounds, allowing time for any binding to occur, and assaying for anybound complexes. All such methods are enabled by the present disclosureof substantially pure HLS-5 proteins, substantially pure functionaldomain fragments, fusion proteins, antibodies, and methods of making andusing the same.

As mentioned previously, when administered to cells or when itsexpression levels are high, HLS-5 reduces levels of PIAS1, UB1, UBC9 andSUMO-1, resulting in a reduction of the overall SUMOylation of someprotein targets and the induction of others. Thus in vivo SUMOylationassay is one test for the effect of candidate compounds on the HLS-5transcription factor modulator of the present invention and this can bedone by the administration a variant of HeLa or COS cell, for example,etc. and determine whether cells have altered levels of SUMOylation ofindividual protein products by western analysis.

In some embodiments, the control agents of the present invention relateto the use of RNA interference (RNAi) to reduce expression of one ormore miRNAs encoded by the HLS-5. RNAi constructs comprise doublestranded RNA that can specifically block expression of a target genee.g. HLS-5. “RNA interference” or “RNAi” is a term initially applied toa phenomenon observed in plants and worms where double-stranded RNA(dsRNA) blocks gene expression in a specific and post-transcriptionalmanner. RNAi provides a useful method of inhibiting gene expression invitro or in vivo. RNAi constructs can comprise either long stretches ofdsRNA identical or substantially identical to the HLS-5 nucleic acidsequence or short stretches of dsRNA identical to or substantiallyidentical to only a region of the HLS-5 nucleic acid sequence.

As used herein, the term “RNAi construct” is a generic term includingsmall interfering RNAs (siRNAs), hairpin RNAs, and other RNA specieswhich can be cleaved in vivo to form siRNAs. RNAi constructs herein alsoinclude expression vectors (also referred to as RNAi expression vectors)capable of giving rise to transcripts which form dsRNAs or hairpin RNAsin cells, and/or transcripts which can produce siRNAs in vivo. Incertain embodiments, the RNAi constructs are non-enzymatic nucleicacids.

Optionally, the RNAi constructs contain a nucleotide sequence thathybridizes under physiologic conditions of the cell to the nucleotidesequence of at least a portion of the mRNA transcript for the HLS-5gene. The double-stranded RNA need only be sufficiently similar tonatural RNA so that it has the ability to mediate RNAi. Thus, the RNAiconstructs described herein have the advantage of being able to toleratesequence variations that might be expected due to genetic mutation,strain polymorphism or evolutionary divergence. The number of toleratednucleotide mismatches between the target sequence and the RNAi constructsequence is no more than 1 in 5 base pairs, or 1 in 10 base pairs, or 1in 20 base pairs, or 1 in 50 base pairs. Mismatches in the centre of thesiRNA duplex are most critical and may essentially abolish cleavage ofthe HLS-5 RNA. In contrast, nucleotides at the 3′ end of the siRNAstrand that is complementary to the HLS-5 RNA do not significantlycontribute to specificity of the target recognition. Sequence identitymay be optimized by sequence comparison and alignment algorithms knownin the art (see Gribskov and Devereux, Sequence Analysis Primer,Stockton Press, 1991, and references cited therein) and calculating thepercent difference between the nucleotide sequences by, for example, theSmith-Waterman algorithm as implemented in the BESTFIT software programusing default parameters (e.g., University of Wisconsin GeneticComputing Group). Greater than 90%, 95%, 96%, 97%, 98%, or 99% sequenceidentity, or even 100% sequence identity, between the inhibitory RNA andthe portion of the target gene is preferred. Alternatively, the duplexregion of the RNA may be defined functionally as a nucleotide sequencethat is capable of hybridizing under specified conditions with a portionof the target gene transcript (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1mM EDTA, 50@C. or 70@C. hybridization for 12-16 hours; followed bywashing).

The double-stranded structure may be formed by a singleself-complementary RNA strand or two complementary RNA strands. RNAduplex formation may be initiated either inside or outside the cell. TheRNA may be introduced in an amount which allows delivery of at least onecopy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000copies per cell) of double-stranded material may yield more effectiveinhibition, while lower doses may also be useful for specificapplications. Inhibition is sequence-specific in that nucleotidesequences corresponding to the duplex region of the RNA are targeted forgenetic inhibition.

The subject RNAi constructs can be “small interfering RNAs” or “siRNAs.”These nucleic acids are around 19-30 nucleotides in length, and evenmore preferably 21-23 nucleotides in length. The siRNAs are understoodto recruit nuclease complexes and guide the complexes to the target mRNAby pairing to the specific sequences. As a result, the target mRNA isdegraded by the nucleases in the protein complex. In a particularembodiment, the 21-23 nucleotides siRNA molecules comprise a 3′ hydroxylgroup. In certain embodiments, the siRNA constructs can be generated byprocessing of longer double-stranded RNAs, for example, in the presenceof the enzyme dicer.

Alternatively, the RNAi construct is in the form of a hairpin structure(referred to as hairpin RNA). The hairpin RNAs can be synthesizedexogenously or can be formed by transcribing from RNA polymerase IIIpromoters in vivo. Examples of making and using such hairpin RNAs forgene silencing in mammalian cells are described in, for example,Paddison et al., 2002, Genes Dev, 16:948-58; McCaffrey et al., 2002,Nature, 418:38-9; McManus et al., 2002, RNA, 8:842-50; Yu et al., 2002,Proc Natl Acad Sci USA, 99:6047-52). Preferably, such hairpin RNAs areengineered in cells or in an animal to ensure continuous and stablesuppression of the HLS-5. It is known in the art that siRNAs can beproduced by processing a hairpin RNA in the cell.

In another embodiment, the control agents are ribozyme moleculesdesigned to catalytically cleave HLS-5 mRNA transcripts to preventtranslation of mRNA (see, e.g., PCT International PublicationWO90/11364, published Oct. 4, 1990; Sarver et al., 1990, Science247:1222-1225; and U.S. Pat. No. 5,093,246). While ribozymes that cleavemRNA at site-specific recognition sequences can be used to destroy HLS-5mRNAs, the use of hammerhead ribozymes is preferred. Hammerheadribozymes cleave mRNAs at locations dictated by flanking regions thatform complementary base pairs with the target mRNA. The sole requirementis that the target mRNA has the following sequence of two bases:5′-UG-3′. The construction and production of hammerhead ribozymes iswell known in the art and is described more fully in Haseloff andGerlach, 1988, Nature, 334:585-591. The ribozymes of the presentinvention also include RNA endoribonucleases (hereinafter “Cech-typeribozymes”) such as the one which occurs naturally in Tetrahymenathermophila (known as the IVS or L-19 IVS RNA) and which has beenextensively described (see, e.g., Zaug et al., 1984, Science,224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug et al.,1986, Nature, 324:429-433; published International patent applicationNo. WO88/04300 by University Patents Inc.; Been and Cech, 1986, Cell,47:207-216).

In another embodiment, the control agents are antisense nucleic acidswhich can readily be synthesized using recombinant means, or aresynthesized in vitro. Equipment for such synthesis is sold by severalvendors, including Applied Biosystems. The preparation of otheroligonucleotides such as phosphorothioates and alkylated derivatives isalso well known to those of skill in the art.

Antisense molecules as used herein include anti-sense or senseoligonucleotides. Sense oligonucleotides can, eg., be employed to blocktranscription by binding to the anti-sense strand. The anti-sense andsense oligonucleotide comprise a single-stranded nucleic acid sequence(either RNA or DNA) capable of binding to target mRNA (sense) or DNA(anti-sense) sequences for PKC isozyme molecules. Anti-sense or senseoligonucleotides, according to the present invention, comprise afragment generally at least about 14 nucleotides, preferably from about14 to 30 nucleotides. The ability to derive an anti-sense or a senseoligonucleotide, based upon a cDNA sequence encoding a given protein isdescribed in, eg., Stein & Cohen (Cancer Res. 48:2659 (1988 and van derKrol et al. 1988, Bio Techniques, 6:958).

By “comprising” is meant including, but not limited to, whatever followsthe word comprising”. Thus, use of the term “comprising” indicates thatthe listed elements are required or mandatory, but that other elementsare optional and may or may not be present. By “consisting of” is meantincluding, and limited to, whatever follows the phrase “consisting of”.Thus, the phrase “consisting of” indicates that the listed elements arerequired or mandatory, and that no other elements may be present. By“consisting essentially of” is meant including any elements listed afterthe phrase, and limited to other elements that do not interfere with orcontribute to the activity or action specified in the disclosure for thelisted elements. Thus, the phrase “consisting essentially of” indicatesthat the listed elements are required or mandatory, but that otherelements are optional and may or may not be present depending uponwhether or not they affect the activity or action of the listedelements.

The following examples, which describe exemplary techniques andexperimental results, are provided for the purpose of illustrating theinvention, and should not be construed as limiting.

Example 1 Co-Association of Protein Inhibitors of Activated Stat (PIAS)and the E3-Ligase HLS-5

Using full-length HLS5 as bait, a yeast two-hybrid screen was performed,which identified the protein inhibitor of activated Stat1 (PIAS1) as anovel HLS5 binding protein. In order to further characterize thisinteraction, deletion mutants of the different functional domains of theHLS5 protein were tested for their ability to bind to PIAS1. FIG. 1shows that in the absence of the N terminal portion of HLS5 theinteraction was lost and that the CC domain is essential for interactionbetween these two proteins.

The in vivo association between HLS5 and PIAS was investigated byco-immunoprecipitation assays. FIG. 2 shows that co-transfection ofFlag-tagged PIAS3 and HLS5-GFP, followed by immunoprecipitation withantibodies to GFP, resulted in the co-immunoprecipitation of Flag-PIAS3with HLS5. This co-precipitation was enhanced by exposure of the cellsto the proteasomal inhibitor MG132. These results demonstrate that HLS5and PIAS interact, albeit transiently, in vivo.

In order to assess the localization of these two proteins, COS7 cellswere transfected with FLAG-PIAS1 or FLAG-PIAS3 in the presence ofHLS-5-GFP. Following incubation of the cells in the presence or absenceof proteasome inhibitor MG132, the cells were subjected to fluorescencemicroscopy. As shown in FIG. 3, FLAG-PIAS1 and FLAG-PIAS3 colocalisedwith HLS-5 at nuclear foci. This co-localisation was increased byincubation of the cells with proteasomal inhibitor MG132. Theseexperiments demonstrate that, in addition to the molecular interactionbetween HLS5 and PIAS family members, these proteins colocalize at sitesof transcriptional regulation.

Example 2 Physical and Functional Targeting of PIAS by HLS5

To assess the biological significance of HLS-5 co-localisation andinteraction with PIAS, the levels of PIAS expression and PIAS activityfollowing co-transfection of cells with PIAS and HLS5 plasmid constructswere examined. As shown in FIG. 4, expression of exogenous HLS5,resulted in a specific reduction of the transfected PIAS1 protein level.

In light of the role of PIAS in transcriptional regulation, themodulation of PIAS levels by HLS-5 could influence gene expression.

PIAS1 was first isolated as Protein Inhibitor of Activated STAT1. Toassay PIAS activity, the γ-interferon activated sequence (GAS) andinterferon sequence response element (ISRE) luciferase reporters ofSTAT-mediated transcription were used. As shown in FIG. 5, expression ofexogenous HLS5 in Hela cells greatly increased the transcriptionalactivity of the GAS promoter element, but had no discernable effect onthe ISRE promoter. These results demonstrate that HLS5 operates as aspecific transcriptional activator of the JAK/STAT signaling cascades.

PIAS1 levels have been shown to be lower in more mature macrophagessuggesting that its reduction is required to allow STAT1 to play itscentral role in this differentiation process (Coccia et al., 2002, CellSignal, 14(6): p 537-45). In FIG. 6, it is shown that factors thatinduce myeloid differentiation, such as IL-6 in M1 myeloid cells and PMAin HL-60 cells, caused a significant increase in HLS5 proteinexpression. STAT1 and STAT3 have long been reported to undergoactivation via interferon-γ, and interleukin-6 family members (IL-6,CT-1 or LIF) signaling. This may be explained by our finding that HLS-5can target PIAS, thereby resulting in STAT activation and a diverse setof STAT-mediated cellular responses to cytokines, such as apoptosis,cell cycle control, and differentiation.

These results identify PIAS as a target of HLS5. Since HLS5 suppressesPIAS protein levels and PIAS affects transcription, it can be derivedthat HLS5 plays a role in cell proliferation, migration, anddifferentiation by affecting PIAS-mediated regulation of STATs, andother transcription factors including NF-KB/IKB and p53.

Example 3 Auto-Ubiquitination of HLS5

HLS5 is an RBCC protein, which is part of a large protein family,representing a class of single protein RING finger ubiquitin E3 ligases.FIG. 7 shows the structural domains of HLS5 and describes other humanTRIM/RBCC proteins with E3 ubiquitin ligase activity in vitro or invivo. As shown in FIG. 8, it was examined whether HLS5 also exhibits E3ubiquitin ligase activity. This was done by assay of HLS-5auto-ubiquitination in vivo. It was found that HLS5 undergoesauto-ubiquitination, as evidenced by high-molecular-weight products onanti-HA-ubiquitin Western blots of immunoprecipitated full-length HLS5,relative to RING deleted (ΔN61, ΔN150) or inactivated (C2124) HLS5.

Example 4 PIAS as an E3 Ligase Substrate of HLS-5

Since example 2 shows that HLS5 can reduce the levels of PIAS1 in vivo,it was also examined whether HLS5 indeed ubiquitinates PIAS1. Followingtransfection of the cells with Flag-PIAS1 and HA-tagged ubiquitin, PIAS1was immunoprecipitated and ubiquitination determined by anti_HA-Westernblot. As shown in FIG. 9, the presence of HLS5-GFP, but not GFP,resulted in ubiquitination of PIAS.

Thus, it was found that HLS5 and PIAS are targeted to transcriptionregulatory sites in the nucleus. Further, Hls5 and PIAS physicallyinteract, leading to ubiquitination and proteasomal targeting of PIAS.The resulting decrease in PIAS levels leads to increased transcriptionby STATs and other factors regulated by PIAS.

Example 5 Targeting of HLS-5 by siRNA-Mediated Inhibition of HLS5Expression

The discovery of RNA interference (RNAi) in eukaryotic cells has beenthe major recent breakthrough in molecular and cell biology. Smallinterfering RNA (siRNA) and microRNA (miRNA) are small RNAs of 18-25nucleotides (nt) in length that play important roles in regulating geneexpression. They are incorporated into an RNA-induced silencing complex(RISC) and serve as guides for silencing their corresponding targetmRNAs based on complementary base-pairing.

Knock-down by siRNA-mediated targeting of transcripts has emerged as oneof the most important new technological developments in biomedicalresearch. This technology allows examination of the role and function oftarget genes by knock-down, rather than by over-expression. This greatlydecreases the possibility for experimental artefacts. Further, bypermitting selective silencing of gene expression, siRNAs also holdgreat potential as therapeutic agents. In order to apply this technologyto HLS5, pooled RNA oligonucleotides were tested for their ability toknock-down HLS5 protein levels in cells. This knock-down was assayedfollowing expression of GFP-tagged HLS5 in Cos cells. Expression of theHLS5-GFP in Cos cells permitted the assaying of its expression byanti-GFP Western blotting. An advantage of this experimental system isthat it could readily be tested using pre-validated siRNAs directedagainst GFP.

Using this assay system we identified a second-generation siRNASmartpool (Dharmacon D-006952) that could knock-down HLS5-GFP levels(RMS, experiment #151). This knock-down result was developed further byexamination of the activity of the individual RNA oligonucleotidescontained in this Smartpool. Using the same HLS5-GFP assay system, itwas found that oligo 06 reproducibly knocked-down GFP-HLS5 levels (seeFIG. 10). This result paves the way for the use of HLS5 siRNA tomodulate HLS5 functions.

1. A transcription factor modulator comprising: (i) apharmaceutically-effective amount of an HLS-5 polypeptide, isoformthereof, functional fragment thereof, or pharmaceutical compositionthereof, or (ii) a compound or composition capable of regulating theendogenous levels of HLS-5 or its activity; or (iii) combinationsthereof.
 2. The transcription factor modulator of claim 1, wherein saidmodulator is a ubiquitin ligase comprising: (i) apharmaceutically-effective amount of an HLS-5 polypeptide, isoformthereof, functional fragment thereof, or pharmaceutical compositionthereof; or (ii) a compound or composition capable of regulating theendogenous levels of HLS-5 or its activity; or (iii) combinationsthereof.
 3. The transcription factor modulator of claim 1, wherein theHLS-5 polypeptide comprises the sequence set out in SEQ ID NO:2, SEQ IDNO:4, or SEQ ID NO:6, or a polypeptide substantially homologous thereto,or a functional fragment thereof.
 4. The transcription factor modulatorof claim 1, wherein the HLS-5 polypeptide is expressed in vivo from avector comprising a polynucleotide encoding HLS-5.
 5. The transcriptionfactor modulator of claim 4, wherein the HLS-5 polynucleotide isselected from the group consisting of: (a) polynucleotides comprisingthe nucleotide sequence set out in SEQ ID NO: 1, SEQ ID NO:3, or SEQ IDNO:5, or a functional fragment thereof; (b) polynucleotides comprising anucleotide sequence capable of hybridizing selectively to the nucleotidesequence set out in SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5, or afunctional fragment thereof; (c) polynucleotides comprising apolynucleotide sequence which is degenerate as a result of the geneticcode to the polynucleotides defined in (a) or (b); (d) polynucleotidescomplementary to the polynucleotides of (a) or (b).
 6. The transcriptionfactor modulator of claim 5, wherein the HLS-5 polynucleotide isoperably linked to regulatory sequences capable of directing expressionof said polynucleotide in a host cell.
 7. A method of modulatingtranscription factor activity in vivo comprising the step ofadministering to a subject in need thereof the transcription factormodulator of claim
 1. 8. The method of claim 7, wherein thetranscription factor modulator will directly or indirectly preventtranscription factor function or activity.
 9. The method of claim 7,wherein the transcription factor modulator will directly or indirectlybring about or enhance transcription factor activity.
 10. A method ofmodulating transcription factor activity in vitro comprising the step ofadministering to cells: (i) a pharmaceutically-effective amount of anHLS-5 polypeptide, isoform thereof, functional fragment thereof, orpharmaceutical composition thereof; or (ii) a compound or compositioncapable of regulating the endogenous levels of HLS-5 or its activity; or(iii) combinations thereof.
 11. A method for treating or preventing acondition associated with transcription factor dysregulation comprisingthe step of administering to a subject in need thereof: (i) apharmaceutically-effective amount of an HLS-5 polypeptide, isoformthereof, functional fragment thereof, or pharmaceutical compositionthereof; or (ii) a compound or composition capable of regulating theendogenous levels of HLS-5 or its activity; or (iii) combinationsthereof.
 12. The method of claim 11, wherein the condition will bedirectly affected by or controlled by transcription factors.
 13. Themethod of claim 11, wherein the administration of the transcriptionfactor modulator improves, alleviates, or treats the condition bycontrolling the transcription factors associated with or affected by thecondition.